



Blue Berry Pharma Advisory



EUROPEAN PHARMACEUTICAL MARKET: TRENDS AND INSIGHTS

| MAT 2022 Q3

— IQVIA MIDAS-Europe 2022

By:
Anshu Aman
MBA-Pharmaceutical Management
IIHMR-U, Jaipur

Under the Guidance of:
Mr. Subhash Seth
CEO
Blue Berry Pharma Advisory

Contents

Introduction: European Pharmaceutical Market

The pharmaceutical industry is one of the most vital sectors of the global economy, and Europe's pharmaceutical market is no exception. With a highly competitive market and rapidly changing healthcare landscape, it is crucial to analyze the market's performance to identify opportunities and challenges.

This market analysis aims to provide a comprehensive understanding of the European pharmaceutical market from MAT 2020(Q3) to MAT 2022(Q3).

Study Design

Type of Research: Qualitative
Data Collection method: Secondary Data
Data analysis method: Descriptive analysis, Statistical Analysis

By Geography

Market Overview

- Market Size
- Market Share
- Quarterly trends

Regional Segmentation

- ERM Member States
- Key 5 Countries
- Others



By Sector

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



By Therapeutic Category

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



Biosimilars in Europe

Introduction
Market Overview
Regulatory Landscape
Oncology Biosimilars

- Molecules details
- Product details





Introduction: European Pharmaceutical Market

The pharmaceutical industry is one of the most vital sectors of the global economy, and Europe's pharmaceutical market is no exception. With a highly competitive market and rapidly changing healthcare landscape, it is crucial to analyze the market's performance to identify opportunities and challenges.

This market analysis aims to provide a comprehensive understanding of the European pharmaceutical market from MAT 2020(Q3) to MAT 2022(Q3).

Objectives:

The aims and objectives of this study are:

1. Importance of the European pharmaceutical industry in the global marketplace.
2. Examination of MAT 2020(Q3) to MAT 2022(Q3) to identify areas of growth and challenges.
3. Emerging trends in Europe's pharmaceutical landscape, including increased usage of and adoption of biosimilars.
4. Charting paths forward through collaboration and strategic initiatives for positive outcomes in the pharmaceutical sector.
5. Comprehending Key Players who are contributing significantly

IQVIA's MIDAS Dataset

The MIDAS dataset is used by pharmaceutical companies, payers, and other healthcare stakeholders to make informed decisions about product development, pricing, and marketing.

It can be used to track market trends, identify new opportunities, and assess the competitive landscape.

The MIDAS dataset that has been used in this study is of Europe Sept. 2022. The aim of procuring the IQVIA's MIDAS dataset was to track market trends, the growth of new therapeutic areas, the decline of older products, and the changing patterns of patient care.



Data Overview:

IQVIA's Europe Coverage:
33 Countries

25 EMA Countries:

Austria,
Bulgaria,
Czech Republic,
Finland,
Germany,
Hungary,
Italy
Lithuania
Netherlands
Poland
Romania
Slovenia
Sweden

Belgium,
Croatia,
Estonia,
France,
Greece,
Ireland,
Latvia
Luxembourg
Norway
Portugal
Slovakia
Spain

8 Non-EMA Countries-

Belarus,
Bosnia and Herzegovina,
Kazakhstan,
Russia,
Serbia,
Switzerland,
Turkey,
United Kingdom

Top 5 Countries

Germany
France
Italy
United Kingdom
Spain

Missing Countries-

Denmark,
Ukraine
(Possible Reason: Ongoing War)

Contents

Introduction: European Pharmaceutical Market

The pharmaceutical industry is one of the most vital sectors of the global economy, and Europe's pharmaceutical market is no exception. With a highly competitive market and rapidly changing healthcare landscape, it is crucial to analyze the market's performance to identify opportunities and challenges.

This market analysis aims to provide a comprehensive understanding of the European pharmaceutical market from MAT 2020(Q3) to MAT 2022(Q3).

Study Design

Type of Research: Qualitative
Data Collection method: Secondary Data
Data analysis method: Descriptive analysis, Statistical Analysis

By Geography

Market Overview

- Market Size
- Market Share
- Quarterly trends

Regional Segmentation

- ERM Member States
- Key 5 Countries
- Others



By Sector

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



By Therapeutic Category

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



Biosimilars in Europe

Introduction
Market Overview
Regulatory Landscape
Oncology Biosimilars

- Molecules details
- Product details





Study Design

Type of Research: Qualitative

Data Collection method: Secondary Data

Data analysis method: Descriptive analysis, Statistical Analysis


Descriptive Analysis

- Since the dataset was huge, so to calculate revenue range, the skewed data was converted into normal distribution by taking the logarithmic value of revenue of all the products. Then the standard deviation was calculated and using Z-Score, the range was calculated.
- Similar step was repeated to calculate the range for growth rate and then a matrix was created.


REVENUE		GROWTH RATE						
			A+	A	B+	B	C+	C
High	A+	A+	A+A+	A+A	A+B+	A+B	A+C+	A+C
	A	A	AA+	AA	AB+	AB	AC+	AC
Medium	B+	B+	B+A+	B+A	B+B+	B+B	B+C+	B+C
	B	B	BA+	BA	BB+	BB	BC+	BC
Low	C+	C+	C+A+	C+A	C+B+	C+B	C+C+	C+C
	C	C	CA+	CA	CB+	CB	CC+	CC



SKEWD DATASET


Average unit price




Q3 2022_LEU MNF












Average Revenue



LOG Curve





Revenue Range

Category	Min		Max	
C	€	0.5	€	1,000
C+	€	1,000	€	9,999
B	€	10,003	€	149,986
B+	€	150,000	€	999,962
A	€	1,000,196	€	99,181,393
A+	€	101,037,483	€	1,062,559,598

Growth Rate:

Growth Rate		
	-9646675%	0%
C	0%	2%
C+	2%	14%
B	14%	104%
B+	104%	767%
A	767%	5558%
A+	5560%	865245218%

Contents

Introduction: European Pharmaceutical Market

The pharmaceutical industry is one of the most vital sectors of the global economy, and Europe's pharmaceutical market is no exception. With a highly competitive market and rapidly changing healthcare landscape, it is crucial to analyze the market's performance to identify opportunities and challenges.

This market analysis aims to provide a comprehensive understanding of the European pharmaceutical market from MAT 2020(Q3) to MAT 2022(Q3).

Study Design

Type of Research: Qualitative
Data Collection method: Secondary Data
Data analysis method: Descriptive analysis, Statistical Analysis

By Geography

Market Overview

- Market Size
- Market Share
- Quarterly trends

Regional Segmentation

- ERM Member States
- Key 5 Countries
- Others



By Sector

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



By Therapeutic Category

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



Biosimilars in Europe

Introduction
Market Overview
Regulatory Landscape
Oncology Biosimilars

- Molecules details
- Product details





By Geography

Market Overview

- Market Size
- Market Share
- Quarterly trends

Regional Segmentation

- EMA Member States
- Key 5 Countries
- Others



Market Overview:

The European pharmaceutical market is **growing steadily**, with an average annual growth rate of **7-11%** over last three years.

In 2022 Q3, the total pharmaceutical market's revenue was €282.8 bn. which is a significant increase from the revenue in 2021 Q3 (€253.9 bn.) and 2020 Q3 (€241.1 bn).


Revenue

Units Sold

Similarly, the total units sold in 2022 Q3 (38,626,182,527) were higher than those in 2021 Q3 (36,874,963,408) and 2020 Q3 (38,103,063,031).




Pharmaceutical Market Size of different Countries vs. Population



European Pharmaceutical Market Country Wise Quarterly Trend

Top Countries


Bottom Countries

Source: <https://public.flourish.studio/visualisation/13054286/>Web Viewer [Terms](#) [Privacy & Cookies](#)

Key 5 Vs. Others

Revenue	MAT 2022 Q3	MAT 2021 Q3	MAT 2020 Q3
Hospital	€110 bn.	€97 bn.	€88 bn.
Retail	€173 bn.	€157 bn.	€153 bn.
European Pharmaceutic al Mkt.	€283 bn.	€254 bn.	€241 bn.

Rest of Europe



Key 5 countries

Market Share:

Flourish

Market Share

By Anshu Aman on 21 May 2023



All Key5 Others




Enter year for detailed view

Country: Germany France Italy UK Spain Russia Poland Turkey Belgium
Switzerland Austria Sweden Portugal Romania Netherlands Czech Republic Greece
Hungary Finland Norway Ireland Bulgaria Slovakia Kazakhstan Croatia Serbia
Belarus Lithuania Slovenia Latvia Bosnia Estonia Luxembourg

MS 2020


MS 2021

MS 2022



European Pharma Market Vs. Population (Countrywise)					Revenue (in Billion Euros)		
Country	Capital	EMA	Population(as on 2021)	Area (Sq. km.)	2022(Q3)	2021(Q3)	2020(Q3)
Austria	Vienna	Yes	8955797	83871	€ 5.7	€ 5.1	€ 4.8
Belarus	Minsk	No	9340314	207600	€ 0.8	€ 0.8	€ 0.7
Belgium	City of Brussels	Yes	11592952	30528	€ 6.4	€ 6.5	€ 6.2
Bosnia and Herzegovina	Sarajevo	No	3270943	51197	€ 0.4	€ 0.3	€ 0.3
Bulgaria	Sofia	Yes	6877743	110879	€ 2.0	€ 1.8	€ 1.6
Croatia	Zagreb	Yes	3899000	56594	€ 1.2	€ 1.1	€ 1.0
Czech Republic	Prague	Yes	10505772	78867	€ 3.8	€ 3.3	€ 3.1
Estonia	Tallinn	Yes	1330932	45228	€ 0.3	€ 0.3	€ 0.3
Finland	Helsinki	Yes	5541017	338145	€ 2.8	€ 2.7	€ 2.7
France	Paris	Yes	67749632	643801	€ 38.9	€ 34.8	€ 33.2
Germany	Berlin	Yes	83196078	357022	€ 50.3	€ 46.6	€ 43.8
Greece	Athens	Yes	10641221	131957	€ 3.1	€ 3.0	€ 2.9
Hungary	Budapest	Yes	9709891	93028	€ 2.8	€ 2.7	€ 2.7
Ireland	Dublin	Yes	5033165	70273	€ 2.7	€ 2.5	€ 2.3
Italy	Rome	Yes	59109668	301340	€ 33.7	€ 30.5	€ 29.3
Kazakhstan	Nur-Sultan	No	19000988	2724900	€ 1.4	€ 1.1	€ 1.2
Latvia	Riga	Yes	1884490	64589	€ 0.4	€ 0.4	€ 0.4
Lithuania	Vilnius	Yes	2800839	65300	€ 0.9	€ 0.8	€ 0.7
Luxembourg	Luxembourg	Yes	640064	2586	€ 0.2	€ 0.2	€ 0.2
Netherlands	Amsterdam	Yes	17533044	41543	€ 3.5	€ 3.3	€ 3.4
Norway	Oslo	Yes	5408320	323802	€ 3.2	€ 2.8	€ 2.4
Poland	Warsaw	Yes	37747124	312685	€ 8.4	€ 7.5	€ 7.3
Portugal	Lisbon	Yes	10325147	92212	€ 4.3	€ 3.9	€ 3.7
Romania	Bucharest	Yes	19119880	238391	€ 4.4	€ 3.7	€ 3.4
Russia	Moscow	No	143449286	17098240	€ 21.1	€ 14.8	€ 15.2
Serbia	Belgrade	No	6834326	77474	€ 1.1	€ 1.0	€ 0.9
Slovakia	Bratislava	Yes	5447247	49035	€ 1.6	€ 1.5	€ 1.5
Slovenia	Ljubljana	Yes	2108079	20273	€ 0.8	€ 0.7	€ 0.7
Spain	Madrid	Yes	47415750	505370	€ 26.7	€ 24.5	€ 22.5
Sweden	Stockholm	Yes	10415811	450295	€ 4.9	€ 4.7	€ 4.4
Switzerland	Bern	No	8703405	41277	€ 6.7	€ 6.0	€ 5.8
Turkey	Ankara	No	84775404	783562	€ 6.5	€ 6.5	€ 7.0
United Kingdom	London	No	67326569	243610	€ 31.4	€ 28.5	€ 25.5
Total		25	635,587,925	-	€ 282.8	€ 253.9	€ 241.1

EMA member states Vs. Key 5 Countries



	Market Share (%)			Growth Rate		
	2022(Q3)	2021(Q3)	2020(Q3)	MAT '22-'21	MAT '21-'20	CAGR
EMA Member States	75%	77%	77%	9%	6%	5.0%
Key 5 countries	64%	65%	64%	10%	7%	5.5%
Total	100%	100%	100%	11%	5%	5%



Insights and Trends:

- The European pharmaceutical market witnessed steady growth over the past two years, with a CAGR of 4.3% from MAT 2020(Q3) to MAT 2022(Q3).
- The biosimilars segment is expected to witness the fastest growth, driven by increasing demand and favorable government policies.
- The market is highly competitive, with several large and small players operating in the region.



Conclusion and Recommendations:

The European pharmaceutical market is expected to continue its growth trajectory over the next few years, driven by the increasing demand for biosimilars, the aging population, and the rising prevalence of chronic diseases. Pharmaceutical companies operating in the region should focus on developing innovative products and expanding their product offerings to capitalize on the market growth. Additionally, companies should focus on building strong partnerships with healthcare providers and payers to improve market access.

Conclusion and Recommendations:

The European pharmaceutical market presents several opportunities and challenges for pharmaceutical companies operating in the region. The increasing demand for biosimilars presents an opportunity for companies to expand their product offerings and gain a competitive advantage. However, companies need to navigate the complex regulatory landscape and stringent requirements for market approval. The aging population presents an opportunity for companies to develop products targeting age-related diseases. However, this also increases the burden on healthcare systems, leading to increased pricing pressure.

Contents

Introduction: European Pharmaceutical Market

The pharmaceutical industry is one of the most vital sectors of the global economy, and Europe's pharmaceutical market is no exception. With a highly competitive market and rapidly changing healthcare landscape, it is crucial to analyze the market's performance to identify opportunities and challenges.

This market analysis aims to provide a comprehensive understanding of the European pharmaceutical market from MAT 2020(Q3) to MAT 2022(Q3).

Study Design

Type of Research: Qualitative
Data Collection method: Secondary Data
Data analysis method: Descriptive analysis, Statistical Analysis

By Geography

Market Overview

- Market Size
- Market Share
- Quarterly trends

Regional Segmentation

- ERM Member States
- Key 5 Countries
- Others



By Sector

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



By Therapeutic Category

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



Biosimilars in Europe

Introduction
Market Overview
Regulatory Landscape
Oncology Biosimilars

- Molecules details
- Product details





By Sector

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



Introduction


The European pharmaceutical market is growing steadily, with a solid **growth rate of 11.38%** from 2021 to 2022, with an **average annual growth rate of 8.35%** over the past three years.

The European Pharmaceutical retail market is growing at a slower rate than the overall pharmaceutical market

The retail sector of the European Pharmaceutical Market was valued at €173 bn. in 2022 Q3, which constitutes around 61% of the market's total revenue.

Although the retail sector is growing, as seen in its increasing revenue from €153 bn. in 2020 Q3 to €157 bn. in 2021 Q3 and finally to €173 bn. in 2022 Q3, its market share is declining. In 2020 Q3, the retail sector had a market share of 63%, which decreased to 62% in 2021 Q3 and further reduced to 61% in 2022 Q3.

Despite the slower growth rate, the retail sector still holds a significant market share and is expected to continue to grow in the future.



Introduction

As per MAT 2022 Q3, the market's revenue totaled €282.8 bn., which is a considerable increase from the revenue in 2021 Q3 (€253.9 bn.) and 2020 Q3 (€241.1 bn.).

Additionally, the total number of units sold in 2022 Q3 (386 Cr.) was higher than in 2021 Q3 (368 Cr.) and 2020 Q3 (381 Cr.).


The hospital sector is becoming a more significant player in the European pharmaceutical market.

The hospital sector of the European Pharmaceutical Market was valued at €110 bn. in 2022 Q3, which constitutes around 39% of the market's total revenue.

The hospital sector's market share was around 37% in 2020 Q3 (€88 bn.), which grew to 38% in 2021 Q3 (€97 bn.)


Between MAT 2020 Q3 and MAT 2022 Q3, the pharmaceutical market of Europe witnessed an increase of €42 bn.

This revenue growth is primarily driven by the hospital sector, which experienced a rise of €22 bn. during the same period.




Top 10 Companies by Pharmaceutical Sales –MAT 2022 (Q3)






Novartis


Revenue in Millions (MAT 2022 Q3)
Units Sold (In Thousands)







Revenue in Millions (MAT 2022 Q3)

Units Sold (In Thousands)





Merck & Co
€ 11.38 billion

Products: 172
Manufacturers: 23

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Eur 7,764 Millions

76%

GENERAL ANTI-INFECTIVES SYSTEMIC
Eur 1,992 Millions

19%

ALIMENTARY TRACT AND METABOLISM
Eur 1,114 Millions


11%



NERVOUS SYSTEM
Eur 285 Millions

3%

CARDIOVASCULAR SYSTEM
Eur 144 Millions

1%





Roche
€ 10.85 billion

Products: 153
Manufacturers: 24

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Eur 5,907 Millions

54%

NERVOUS SYSTEM
Eur 1,983 Millions

18%

BLOOD AND BLOOD FORMING ORGANS
Eur 1,272 Millions

12%

MUSCULO-SKELETAL SYSTEM
Eur 818 Millions


8%


RESPIRATORY SYSTEM
Eur 426 Millions

4%

DIAGNOSTIC AGENTS
Eur 305 Millions

GENERAL ANTI-INFECTIVES SYSTEMIC
Eur 107 Millions








SANOFI

Sanofi
€ 10.56 billion

Products: 796
Manufacturers: 63




Revenue in Millions (MAT 2022 Q3) Units Sold (In Thousands)



**Bristol-Myers
Squibb**


€ 10.36 billion

Products: 132
Manufacturers: 32





Revenue in Millions
(MAT 2022 Q3)


Units Sold (In
Thousands)





Pfizer
€ 9.36 billion
Products 536
Manufacturers: 52




Revenue in Millions (MAT 2022 Q3) Units Sold (In Thousands)



Bayer
€ 8.74 billion
Products: 357
Manufacturers: 35





Revenue in Millions (MAT 2022 Q3) Units Sold (In Thousands)



AstraZeneca


AstraZeneca
€ 8.23 billion

Products: 109
Manufacturers: 15





Revenue in Millions
(MAT 2022 Q3)

Units Sold (In
Thousands)



Viatriis
€ 7.56 billion


Products: 1521
Manufacturers: 63



Revenue in Millions
(MAT 2022 Q3)

Units Sold (In
Thousands)

Summary:



Contents

Introduction: European Pharmaceutical Market

The pharmaceutical industry is one of the most vital sectors of the global economy, and Europe's pharmaceutical market is no exception. With a highly competitive market and rapidly changing healthcare landscape, it is crucial to analyze the market's performance to identify opportunities and challenges.

This market analysis aims to provide a comprehensive understanding of the European pharmaceutical market from MAT 2020(Q3) to MAT 2022(Q3).

Study Design

Type of Research: Qualitative
Data Collection method: Secondary Data
Data analysis method: Descriptive analysis, Statistical Analysis

By Geography

Market Overview

- Market Size
- Market Share
- Quarterly trends

Regional Segmentation

- ERM Member States
- Key 5 Countries
- Others



By Sector

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



By Therapeutic Category

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



Biosimilars in Europe

Introduction
Market Overview
Regulatory Landscape
Oncology Biosimilars



- Molecules details
- Product details





By Therapeutic Category

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly





Therapeutic Category

This Interactive Dashboard of European Pharmaceutical market allows you to drill into the data for Analysis of the market. It also analyzes what types of products are most popular in different regions and provides insights into areas to focus marketing efforts.

This Report is loaded with Power BI Features that will allow the user to understand a large amount of data with an easy to use interface. By integrating Power Apps within this Power BI Report, the users are able to get from Data to Insights to Action rapidly.


Drug Type	Value
ALIMENTARY TRACT AND METABOLISM	621905803404
ANTINEOPLASTIC AND IMMUNOMODULATING A...	423844316128
BLOOD AND BLOOD FORMING ORGANS	252663848020
CARDIOVASCULAR SYSTEM	597401287182
DERMATOLOGICALS	385110604361
DIAGNOSTIC AGENTS	34800300559
GENERAL ANTI-INFECTIVES SYSTEMIC	208444900153
GENITO-URINARY SYSTEM AND SEX HORMONES	100341272724
HOSPITAL SOLUTIONS	34156807631
MUSCULO-SKELETAL SYSTEM	196933080877
NERVOUS SYSTEM	651382000332
PARASITOLOGY	5781618120
RESPIRATORY SYSTEM	599521178332
SENSORY ORGANS	264749469380
SYSTEMIC HORMONAL PREPARATIONS (EXCLUDIN...	90573871579
VARIOUS	43370554768
Total	4510980913550

(Blank)

2020




2021


2022



Generic Product Classification

All






ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS


By: Anshu Aman

Mkt. Size
€66.4 bn
(Avg. of 3 Years)

A **strong demand** for oncology treatments in Europe with significant shift in the market **towards targeted therapies**

- **Antineoplastic category** is the largest in terms of revenue, with over **€47 billion in revenue** in MAT 2022 Q3.
- **Immunomodulating agents** (constituting of Immunostimulanting agents and Immunosuppresants) had a revenue of **€20 billion** in MAT 2022 Q3, with **Cytostatic hormone therapy** generating around **€6.3 billion** in MAT 2022 Q3





Category
Revenue

L: Oncology Mkt.



L1	Antineoplastics	€ 42.4 bn.
L1A	Alkylating agents	€ 0.38 bn.
L1B	Antimetabolites	€ 1.5 bn.
L1C	Plant-Based Antineoplastics	€ 1.25 bn.
L1D	Antineoplastic Antibiotics	€ 0.3 bn.
L1F	Platinum Antineoplastics	€ 0.35 bn.
L1G	Monoclonal Antibody Antineoplastics	€ 19.6 bn.
L1H	Protein Kinase Inhibitor Antineoplastics	€ 12.2 bn.
L1J	Proteasome Inhibitor Antineoplastics	€ 0.85 bn.
L1X	All Other Antineoplastics	€ 1.6 bn.
L1K	Lidomide Antineoplastics	€ 3.4 bn.
L1L	PARP Inhibitor Antineoplastics	€ 0.89 bn.
L2	Cytostatic Hormone Therapy	€ 5.4 bn.
L2A	Cytostatic Hormones	€ 1 bn.
L2B	Cytostatic Hormone Antagonists	€ 4.4 bn.
L3	Immunostimulating agents	€1.5 bn.
L3A	Immunostimulating Agents Excluding Interferons	€ 1.3 bn.
L3B	Interferons	€ 0.2 bn.
L4	Immunosuppressants	€ 17 bn.
L4B	Anti-Tnf Products	€ 8.4 bn.
L4C	Interleukin Inhibitors	€ 4.4 bn.
L4X	Other Immunosuppresants	€4.2 bn.



Net Sales
182.6bn

Units Sold
182.6bn

BIOCOMPARABLE
PRODUCTS

EARLY ENTRY GENERIC
PRODUCTS

GENERIC PRODUCTS

NON CATEGORIZED
PRODUCTS

NON GENERIC
PRODUCTS

OTHER PRODUCTS

ALIMENTARY TRACT ...

ANTINEOPLASTIC A...

BLOOD AND BLOOD ...

CARDIOVASCULAR S...

DERMATOLOGICALS

DIAGNOSTIC AGENTS

GENERAL ANTI-INFE...

GENITO-URINARY SY...

HOSPITAL SOLUTIONS

MUSCULO-SKELETA...

NERVOUS SYSTEM

PARASITOLOGY

RESPIRATORY SYST...

SENSORY ORGANS

SYSTEMIC HORMON...

VARIOUS

EMA Member States



Non EMA Member States



Segmentation by therapeutic category. Revenue Trend

Data updated on 5/24/23, 10:33 AM





Net Sales

347.8bn

Units Sold

347.8bn

BIOCOMPARABLE
PRODUCTS

EARLY ENTRY GENERIC
PRODUCTS

GENERIC PRODUCTS

NON CATEGORIZED
PRODUCTS

NON GENERIC
PRODUCTS

OTHER PRODUCTS

ALIMENTARY TRACT ...

ANTINEOPLASTIC A...

BLOOD AND BLOOD ...

CARDIOVASCULAR S...

DERMATOLOGICALS

DIAGNOSTIC AGENTS

GENERAL ANTI-INFE...

GENITO-URINARY SY...

HOSPITAL SOLUTIONS

MUSCULO-SKELETA...

NERVOUS SYSTEM

PARASITOLOGY

RESPIRATORY SYST...

SENSORY ORGANS

SYSTEMIC HORMON...

VARIOUS

EMA Member States



Non EMA Member States





Net Sales
180.8bn

Units Sold
180.8bn

EARLY ENTRY GENERIC PRODUCTS

GENERIC PRODUCTS

NON CATEGORIZED PRODUCTS

NON GENERIC PRODUCTS

OTHER PRODUCTS

ALIMENTARY TRACT ...

ANTINEOPLASTIC A...

BLOOD AND BLOOD ...

CARDIOVASCULAR S...

DERMATOLOGICALS

DIAGNOSTIC AGENTS

GENERAL ANTI-INFE...

GENITO-URINARY SY...

HOSPITAL SOLUTIONS

MUSCULO-SKELETA...

NERVOUS SYSTEM

PARASITOLOGY


RESPIRATORY SYST...

SENSORY ORGANS

SYSTEMIC HORMON...

VARIOUS

EMA Member States



Non EMA Member States





LIHMR UNIVERSITY

Net Sales
95.7bn

Units Sold
95.7bn

BIOCOMPARABLE
PRODUCTS

GENERIC PRODUCTS

NON CATEGORIZED
PRODUCTS

NON GENERIC PRODUCTS

OTHER PRODUCTS

ALIMENTARY TRACT ...

ANTINEOPLASTIC A...

BLOOD AND BLOOD ...

CARDIOVASCULAR S...

DERMATOLOGICALS

DIAGNOSTIC AGENTS

GENERAL ANTI-INFE...

GENITO-URINARY SY...

HOSPITAL SOLUTIONS

MUSCULO-SKELETA...

NERVOUS SYSTEM

PARASITOLOGY


RESPIRATORY SYST...

SENSORY ORGANS


SYSTEMIC HORMON...

VARIOUS

EMA Member States



Non EMA Member States



Contents

Introduction: European Pharmaceutical Market

The pharmaceutical industry is one of the most vital sectors of the global economy, and Europe's pharmaceutical market is no exception. With a highly competitive market and rapidly changing healthcare landscape, it is crucial to analyze the market's performance to identify opportunities and challenges.

This market analysis aims to provide a comprehensive understanding of the European pharmaceutical market from MAT 2020(Q3) to MAT 2022(Q3).

Study Design

Type of Research: Qualitative
Data Collection method: Secondary Data
Data analysis method: Descriptive analysis, Statistical Analysis

By Geography

Market Overview

- Market Size
- Market Share
- Quarterly trends

Regional Segmentation

- ERM Member States
- Key 5 Countries
- Others



By Sector

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



By Therapeutic Category

- Market Overview
- Market Size
- Top 10 Countries Trend - Quarterly



Biosimilars in Europe

Introduction
Market Overview
Regulatory Landscape
Oncology Biosimilars

- Molecules details
- Product details





Biosimilars in Europe


Introduction

Market Overview

Regulatory Landscape

Oncology Biosimilars

- Molecules details
- Product details





Introduction

Biosimilars are biological products that are highly similar to reference products, with no clinically meaningful differences in terms of safety, purity, and potency.

The European biosimilars market for oncology drugs has grown significantly over the past few years due to increased competition, patent expiration, and the need for affordable treatment options.



Biosimilars in Europe: Market Overview

- The Biosimilar market in Europe is growing at a significant rate, with an average annual growth rate (AAGR) of 19% and a compound annual growth rate (CAGR) of 12%.
- Adalimumab is the most popular molecule in the market, with Amgevita being the top-selling brand.
- Other top-performing brands in the Adalimumab category include Hyrimoz and Hulio, both of which have seen substantial YoY growth.
- Idacio and Aybintio have seen massive growth in the Adalimumab category, with YoY growth rates of 158% and 86%, respectively.
- Bevacizumab has also seen significant growth in the market, with Alymsys and Aybintio being the top-performing brands in this category.



Biosimilars in Europe: Market Overview

- Enoxaparin Sodium is another molecule that has shown strong growth, with Enoxaparin ROVI being the top-selling brand.
- Gemapaxane and Enoxapa.BEC-OF-MR7 are two brands that have entered the market recently.
- The market for Epoetin Alfa has remained steady, with Binocrit being the top-selling brand.
- Etanercept is another molecule that has seen significant growth, with Benepali being the top-selling brand.
- The Biosimilar market in Europe is highly competitive, with a large number of brands vying for market share.
- Overall, the Biosimilar market in Europe presents significant opportunities for growth and expansion, particularly in the Adalimumab and Enoxaparin Sodium categories.



Regulatory Landscape of Biosimilar

- The regulatory landscape for biosimilars in Europe is governed by the European Medicines Agency (EMA).
- Biosimilars are required to undergo a rigorous approval process, including preclinical and clinical studies, to ensure their safety and efficacy.
- The EMA has approved a total of 73 biosimilars as of January 2021.

European Biosimilars Market



17 Molecules

ALIMENTARY TRACT AND METABOLISM	INSULIN ASPART
	INSULIN GLARGINE
	INSULIN LISPRO
BLOOD AND BLOOD FORMING ORGANS	ENOXAPARIN SODIUM
	EPOETIN ALFA
	EPOETIN ZETA
GENITO-URINARY SYSTEM AND SEX HORMONES	FOLLITROPIN ALFA
SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES)	SOMATROPIN
	TERIPARATIDE
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ADALIMUMAB
	BEVACIZUMAB
	ETANERCEPT
	FILGRASTIM
	INFLIXIMAB
	PEGFILGRASTIM
	RITUXIMAB
	TRASTUZUMAB



Overall Market Analysis

The European biosimilars market for oncology drugs has seen an overall growth, with total revenues increasing from €2 billion in 2021 (Q3) to €2.4 billion in 2022 (Q3)

	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021- 22)	YoY GR (2020- 21)	AAGR	CAGR	MS 2022	MS 2021	MS 2020	Average MS
Antineoplastic Biosimilars Total	€ 2,394,196,295	€ 2,076,791,316	€ 1,577,702,341	€ 2,016,229,984	GROWING	15%	32%	23%	15%	10%	11%	9%	10%
GRAND TOTAL (3 molecules)	€ 3,595,982,820	€ 3,709,330,680	€ 4,207,425,124	€ 3,837,579,541	DECLINING	-3%	-12%	-7%	-5%	15%	19%	25%	19%
Antineoplastic Total	€ 24,356,332,834	€ 19,777,137,989	€ 16,785,235,162	€ 20,306,235,328	GROWING	23%	18%	20%	13%	100.0%	100.0%	100.0%	100.0%



Antineoplastic Biosimilar Market

European Oncology Biosimilars Mkt						
ATC Code	Therapeutic Category	Molecule	MAT 2022 Q3	MAT 2021 Q3	MAT 2020 Q3	Count of Biosimilar Products
L1G	Monoclonal Antibody Antineoplastics (3)	BEVACIZUMAB	967,158,102	650,263,629	132,331,615	235
		RITUXIMAB	867,203,066	821,142,533	824,931,582	232
		TRASTUZUMAB	559,835,127	605,385,154	620,439,144	225
L3A	Immunostimulating Agents Excluding Interferons (2)	FILGRASTIM	401,845,176	394,165,498	386,080,680	662
		PEGFILGRASTIM	291,985,401	258,370,345	196,929,028	289
L4B	Anti-Tnf Products (3)	ADALIMUMAB	2,456,823,995	1,966,303,564	1,423,295,491	808
		ETANERCEPT	900,838,463	848,302,584	794,427,691	393
		INFLIXIMAB	1,546,294,395	1,404,694,905	1,243,152,815	475
Overall Market			7,991,983,725	6,948,628,212	5,621,588,046	3,319



BEVACIZUMAB

MARKET INSIGHT

Biosimilar products of Bevacizumab are gaining traction in Europe.

A significant increase in revenue and market share from 2020 to 2022 can be observed



Bevacizumab

Blue Berry Pharma Advisory

- Overview:

Bevacizumab is a monoclonal antibody used to treat various types of cancer. In Europe, it is available as a reference product and several biosimilar products. In 2022 Q3, the Bevacizumab market in Europe was valued at €1,2 bn. and it was recovering with a growth rate of 2% YoY. The biosimilar products dominated the market with a market share of 78.1%, while the reference product accounted for 20.1%. The remaining 1.8% belonged to other non-reference products and generics.

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ABEVMY	VIATRIS	Biosimilar	€ 8,362,933	€ 90,492		○ € 4,226,713		9142%		9142%			0.7%	0.0%	0.0%	0.3%
ALYMSYS	ZENTIVA	Biosimilar	€ 66,158,378	€ 3,259,512		○ € 34,708,945		1930%		1930%			5.3%	0.3%	0.0%	2.7%
AYBINTIO	BIOCAD	Biosimilar	€ 174,774,667	€ 93,846,087	€ 465,614	○ € 89,695,456		86%	20055%	10071%	621%		14.1%	7.7%	0.0%	7.0%
AVERGRA	ORGANON	Biosimilar	€ 105,405,829	€ 78,586,449	€ 87,722,258	○ € 90,571,512		34%	-10%	12%	6%		8.5%	6.5%	6.3%	7.1%
MVASI	AMGEN	Biosimilar	€ 377,078,952	€ 282,217,394	€ 23,700,192	● € 227,665,513		34%	1091%	562%	152%		30.4%	23.3%	1.7%	17.8%
OYAVAS	STADA	Biosimilar	€ 62,356,446	€ 7,014,405		○ € 34,685,426		789%		789%			5.0%	0.6%	0.0%	2.7%
ZIRABEV	PFIZER	Biosimilar	€ 172,167,306	€ 185,249,290	€ 20,443,551	○ € 125,953,382		-7%	806%	400%	103%		13.9%	15.3%	1.5%	9.8%
CIZUMAB	HETERO LABS.	Biosimilar	€ 1,984			○ € 1,984							0.0%	0.0%	0.0%	0.0%
BEVAX	ABDI IBRAHIM	Biosimilar	€ 851,607			○ € 851,607							0.1%	0.0%	0.0%	0.1%
Bevacizumab Biosimilars Total			€ 967,158,102	€ 650,263,629	€ 132,331,615	● € 583,251,115		49%	391%	220%	94%		78.1%	53.6%	9.5%	45.6%
AVASTIN	ORIFARM	Reference Product	€ 248,412,533	€ 556,045,908	€ 1,246,049,514	● € 683,502,652		-55%	-55%	-55%	-42%		20.1%	45.8%	89.9%	53.4%
All other non reference products B-MAB, VERSAVO			€ 13,985,079	€ 1,150,358	€ 2,652,997	€ 5,929,478		1116%	-57%	530%	74%		1.1%	0.1%	0.2%	0.5%
All Generic products			€ 9,006,078	€ 6,283,552	€ 4,645,382	€ 6,645,004		43%	35%	39%	25%		0.7%	0.5%	0.3%	0.5%
TOTAL			€ 1,238,561,792	€ 1,213,743,447	€ 1,385,679,508	€ 1,279,328,249		2%	-12%	-5%	-4%		100.0%	100.0%	100.0%	100.0%



- Market Share:

Among the biosimilar products, Mvasi by Amgen had the highest market share of 30.4%, followed by Aybintio by Biocad with 14.1% and Zirabev by Pfizer with 13.9%. The rest of the biosimilar products had a market share ranging from 0.1% to 8.5%. The reference product, Avastin by Orifarm, had a market share of 20.1%, and all other non-reference products and generics combined had a market share of 1.8%.

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ABEVMY	VIATRIS	Biosimilar	€ 8,362,933	€ 90,492		○ € 4,226,713		9142%		9142%			0.7%	0.0%	0.0%	0.3%
ALYMSYS	ZENTIVA	Biosimilar	€ 66,158,378	€ 3,259,512		○ € 34,708,945		1930%		1930%			5.3%	0.3%	0.0%	2.7%
AYBINTIO	BIOCAD	Biosimilar	€ 174,774,667	€ 93,846,087	€ 465,614	○ € 89,695,456		86%	20055%	10071%	621%		14.1%	7.7%	0.0%	7.0%
AVERGRA	ORGANON	Biosimilar	€ 105,405,829	€ 78,586,449	€ 87,722,258	○ € 90,571,512		34%	-10%	12%	6%		8.5%	6.5%	6.3%	7.1%
MVASI	AMGEN	Biosimilar	€ 377,078,952	€ 282,217,394	€ 23,700,192	● € 227,665,513		34%	1091%	562%	152%		30.4%	23.3%	1.7%	17.8%
OYAVAS	STADA	Biosimilar	€ 62,356,446	€ 7,014,405		○ € 34,685,426		789%		789%			5.0%	0.6%	0.0%	2.7%
ZIRABEV	PFIZER	Biosimilar	€ 172,167,306	€ 185,249,290	€ 20,443,551	○ € 125,953,382		-7%	806%	400%	103%		13.9%	15.3%	1.5%	9.8%
CIZUMAB	HETERO LABS.	Biosimilar	€ 1,984			○ € 1,984							0.0%	0.0%	0.0%	0.0%
BEVAX	ABDI IBRAHIM	Biosimilar	€ 851,607			○ € 851,607							0.1%	0.0%	0.0%	0.1%
Bevacizumab Biosimilars Total			€ 967,158,102	€ 650,263,629	€ 132,331,615	● € 583,251,115		49%	391%	220%	94%		78.1%	53.6%	9.5%	45.6%
AVASTIN	ORIFARM	Reference Product	€ 248,412,533	€ 556,045,908	€ 1,246,049,514	● € 683,502,652		-55%	-55%	-55%	-42%		20.1%	45.8%	89.9%	53.4%
All other non reference products B-MAB, VERSAVO			€ 13,985,079	€ 1,150,358	€ 2,652,997	€ 5,929,478		1116%	-57%	530%	74%		1.1%	0.1%	0.2%	0.5%
All Generic products			€ 9,006,078	€ 6,283,552	€ 4,645,382	€ 6,645,004		43%	35%	39%	25%		0.7%	0.5%	0.3%	0.5%
TOTAL			€ 1,238,561,792	€ 1,213,743,447	€ 1,385,679,508	€ 1,279,328,249		2%	-12%	-5%	-4%		100.0%	100.0%	100.0%	100.0%



- Revenue:

The biosimilar products generated a total revenue of €0.96 bn. in 2022 Q3, accounting for 78.1% of the Bevacizumab market. Among them, Mvasi by Amgen had the highest revenue of €0.3 bn., followed by Zirabev by Pfizer with €0.17 bn. and Alymsys by Zentiva with €66,158,378. The revenue of the biosimilar products showed a growth rate ranging from 86% to 9142% YoY. The reference product, Avastin by Orifarm, had a revenue of €248,412,533, accounting for 20.1% of the Bevacizumab market. The revenue of Avastin showed a decline of 55% YoY. The revenue of other non-reference products and generics combined was €13,985,079, accounting for 1.1% of the Bevacizumab market.

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ABEVMY	VIATRIS	Biosimilar	€ 8,362,933	€ 90,492		○ € 4,226,713		9142%		9142%			0.7%	0.0%	0.0%	0.3%
ALYMSYS	ZENTIVA	Biosimilar	€ 66,158,378	€ 3,259,512		○ € 34,708,945		1930%		1930%			5.3%	0.3%	0.0%	2.7%
AYBINTIO	BIOCAD	Biosimilar	€ 174,774,667	€ 93,846,087	€ 465,614	○ € 89,695,456		86%	20055%	10071%	621%		14.1%	7.7%	0.0%	7.0%
AVERGRA	ORGANON	Biosimilar	€ 105,405,829	€ 78,586,449	€ 87,722,258	○ € 90,571,512		34%	-10%	12%	6%		8.5%	6.5%	6.3%	7.1%
MVASI	AMGEN	Biosimilar	€ 377,078,952	€ 282,217,394	€ 23,700,192	● € 227,665,513		34%	1091%	562%	152%		30.4%	23.3%	1.7%	17.8%
OYAVAS	STADA	Biosimilar	€ 62,356,446	€ 7,014,405		○ € 34,685,426		789%		789%			5.0%	0.6%	0.0%	2.7%
ZIRABEV	PFIZER	Biosimilar	€ 172,167,306	€ 185,249,290	€ 20,443,551	○ € 125,953,382		-7%	806%	400%	103%		13.9%	15.3%	1.5%	9.8%
CIZUMAB	HETERO LABS.	Biosimilar	€ 1,984			○ € 1,984							0.0%	0.0%	0.0%	0.0%
BEVAX	ABDI IBRAHIM	Biosimilar	€ 851,607			○ € 851,607							0.1%	0.0%	0.0%	0.1%
Bevacizumab Biosimilars Total			€ 967,158,102	€ 650,263,629	€ 132,331,615	● € 583,251,115		49%	391%	220%	94%		78.1%	53.6%	9.5%	45.6%
AVASTIN	ORIFARM	Reference Product	€ 248,412,533	€ 556,045,908	€ 1,246,049,514	● € 683,502,652		-55%	-55%	-55%	-42%		20.1%	45.8%	89.9%	53.4%
All other non reference products B-MAB, VERSAVO			€ 13,985,079	€ 1,150,358	€ 2,652,997	€ 5,929,478		1116%	-57%	530%	74%		1.1%	0.1%	0.2%	0.5%
All Generic products			€ 9,006,078	€ 6,283,552	€ 4,645,382	€ 6,645,004		43%	35%	39%	25%		0.7%	0.5%	0.3%	0.5%
TOTAL			€ 1,238,561,792	€ 1,213,743,447	€ 1,385,679,508	€ 1,279,328,249		2%	-12%	-5%	-4%		100.0%	100.0%	100.0%	100.0%



Bevacizumab

- Brand Performance:

Among the biosimilar products, Mvasi by Amgen had the highest revenue and market share, indicating strong brand performance. Zirabev by Pfizer and Alymsys by Zentiva also performed well in terms of revenue and market share. The biosimilar products launched in recent years, such as Bevax by Abdi Ibrahim and Cizumab by Hetero Labs, had a very small market share and revenue. The reference product, Avastin by Orifarm, had a declining revenue and market share, indicating weak brand performance.

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ABEVMY	VIATRIS	Biosimilar	€ 8,362,933	€ 90,492		○ € 4,226,713		9142%		9142%			0.7%	0.0%	0.0%	0.3%
ALYMSYS	ZENTIVA	Biosimilar	€ 66,158,378	€ 3,259,512		○ € 34,708,945		1930%		1930%			5.3%	0.3%	0.0%	2.7%
AYBINTIO	BIOCAD	Biosimilar	€ 174,774,667	€ 93,846,087	€ 465,614	○ € 89,695,456		86%	20055%	10071%	621%		14.1%	7.7%	0.0%	7.0%
AVERGRA	ORGANON	Biosimilar	€ 105,405,829	€ 78,586,449	€ 87,722,258	○ € 90,571,512		34%	-10%	12%	6%		8.5%	6.5%	6.3%	7.1%
MVASI	AMGEN	Biosimilar	€ 377,078,952	€ 282,217,394	€ 23,700,192	● € 227,665,513		34%	1091%	562%	152%		30.4%	23.3%	1.7%	17.8%
OYAVAS	STADA	Biosimilar	€ 62,356,446	€ 7,014,405		○ € 34,685,426		789%		789%			5.0%	0.6%	0.0%	2.7%
ZIRABEV	PFIZER	Biosimilar	€ 172,167,306	€ 185,249,290	€ 20,443,551	○ € 125,953,382		-7%	806%	400%	103%		13.9%	15.3%	1.5%	9.8%
CIZUMAB	HETERO LABS.	Biosimilar	€ 1,984			○ € 1,984							0.0%	0.0%	0.0%	0.0%
BEVAX	ABDI IBRAHIM	Biosimilar	€ 851,607			○ € 851,607							0.1%	0.0%	0.0%	0.1%
Bevacizumab Biosimilars Total			€ 967,158,102	€ 650,263,629	€ 132,331,615	● € 583,251,115		49%	391%	220%	94%		78.1%	53.6%	9.5%	45.6%
AVASTIN	ORIFARM	Reference Product	€ 248,412,533	€ 556,045,908	€ 1,246,049,514	● € 683,502,652		-55%	-55%	-55%	-42%		20.1%	45.8%	89.9%	53.4%
All other non reference products B-MAB, VERSAVO			€ 13,985,079	€ 1,150,358	€ 2,652,997	€ 5,929,478		1116%	-57%	530%	74%		1.1%	0.1%	0.2%	0.5%
All Generic products			€ 9,006,078	€ 6,283,552	€ 4,645,382	€ 6,645,004		43%	35%	39%	25%		0.7%	0.5%	0.3%	0.5%
TOTAL			€ 1,238,561,792	€ 1,213,743,447	€ 1,385,679,508	€ 1,279,328,249		2%	-12%	-5%	-4%		100.0%	100.0%	100.0%	100.0%



Biosimilars have gained significant market share:

- The biosimilars of Bevacizumab have experienced tremendous growth in revenue, with an average annual growth rate (AAGR) of 49% and a compound annual growth rate (CAGR) of 53.6% between 2020 and 2022.
- The biosimilar's combined market share increased from 9.5% in 2020 to 45.6% in 2022.
- This indicates a growing preference for biosimilars among healthcare providers and patients, likely due to their lower cost compared to the reference product.
- Avergra by Organon is the only Bevacizumab Biosimilar that has seen a decline in revenue from MAT 2021 to MAT 2022, with a YoY growth rate of -10%



Reference product revenue is declining

- The revenue for the reference product, Avastin, has declined significantly, with a YoY growth rate of -55% in 2022 compared to the previous year.
- This trend is likely due to the increasing competition from biosimilars and the expiration of the product's patent.



AVASTIN

- Reference Product: EMEA/H/C/000582
- Developed by Roche Registration GmbH
- Authorized in the European Union for certain types of cancer, including non-small cell lung carcinoma, breast cancer, ovarian cancer, colorectal cancer, and renal cell carcinoma
- Used in combination with other chemotherapy drugs to improve treatment outcomes
- Works by inhibiting the formation of new blood vessels in tumors, limiting their growth and spread
- Administered by intravenous infusion and requires careful monitoring for potential side effects such as high blood pressure and bleeding
- Not authorized for use in all types of cancer and is not suitable for all patients





Alymsys

- BIOSIMILAR (EMA): EMEA/H/C/005286
- Developed by Mabxience Research SL
- Authorized by EMA on 26.03.2021
- Indicated for Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Uterine Cervical Neoplasms

17 Countries, 2 Pack sizes, 6 Corporation

16 ML. = € 667.44 | 4 ML. = € 155.18





Aybintio

- BIOSIMILAR (EMA): EMEA/H/C/005106
- Developed by Samsung Bioepis NL B.V.
- Authorized by EMA on 19.08.2020
- Indicated for Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Uterine Cervical Neoplasms

9 Countries | 2 pack sizes (1 more in UK) | 2 corporations (Samsung, Organon)

16 ML. = € 711.96 - € 973.98 | 4 ML. = € 186.89 - € 261.67





Vegzelma

- Biosimilar: EMEA/H/C/005534
- Developed by Celltrion Healthcare Hungary Kft.
- Authorized by the European Union to treat several types of cancer, including colorectal cancer, breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, non-small cell lung carcinoma, renal cell carcinoma, and uterine cervical cancer
- Works by inhibiting the formation of new blood vessels in tumors, limiting their growth and spread
- Administered by intravenous infusion and used in combination with other chemotherapy drugs





Onbevzi

- Biosimilar: EMEA/H/C/005640
- Developed by Samsung Bioepis NL B.V.
- Authorized by EMA on 11.01.2021
- Indicated for Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Uterine Cervical Neoplasms



Mvasi

- Biosimilar: EMEA/H/C/004728
- Developed by Amgen Technology (Ireland) UC
- Authorized by EMA on 15.01.2018
- Indicated for Carcinoma, Renal Cell, Peritoneal Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Fallopian Tube Neoplasms



Zirabev

- Biosimilar: EMEA/H/C/004697
- Developed by Pfizer Europe MA EEIG
- Authorized by EMA on 14.02.2019
- Indicated for Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Uterine Cervical Neoplasms



Oyavas

- Biosimilar: EMEA/H/C/005556
- Developed by STADA Arzneimittel AG
- Authorized by EMA on 26.03.2021
- Indicated for Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Uterine Cervical Neoplasms



Abevmy

- Biosimilar: EMEA/H/C/005327
- Developed by Mylan IRE Healthcare Limited
- Authorized by EMA on 21.04.2021
- Indicated for Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Uterine Cervical Neoplasms



- Overview:

Rituximab is a biologic drug that is used for the treatment of various types of cancer, rheumatoid arthritis, and other autoimmune diseases. The market for Rituximab biosimilars has seen significant growth in recent years due to increased competition and patent expirations of the reference product.

RITUXIMAB

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS	
BLITZIMA	OKTAL PHARMA	Biosimilar (EMA)	€ 2,898,579	€ 3,897,593	€ 4,705,530	○ € 3,833,901	Decline	-26%	-17%	-21%	-15%		0.3%	0.3%	0.4%	0.3%	
RITEMVIA	ASTRO-PHARMA GMBH	Biosimilar (EMA)	Discontinued (EMA Mrktng auth. ended in Aug '21)			€ 1,915,576	○ € 1,915,576	Withdrawn		-100%		-100%			0.0%	0.1%	0.2%
RIXATHON	NOVARTIS	Biosimilar (EMA)	€ 526,036,731	€ 401,576,986	€ 333,910,074	● € 420,507,930	Growth	31%	20%	26%	16%		45.7%	34.6%	25.3%	34.7%	
RUXIENCE	PFIZER	Biosimilar (EMA)	€ 72,006,045	€ 31,223,652	€ 395,322	○ € 34,541,673	Growth	131%	7798%		467%		6.3%	2.7%	0.0%	2.9%	
TRUXIMA	CELLTRION	Biosimilar (EMA)	€ 221,402,056	€ 342,586,432	€ 429,854,148	● € 331,280,879	Decline	-35%	-20%	-28%	-20%		19.2%	29.6%	32.6%	27.4%	
ACELBIA	BIOCAD	Biosimilar (Russia)	€ 40,673,669	€ 36,803,922	€ 48,998,585	○ € 42,158,725	Recovery	11%	-25%	16%	-6%		3.5%	3.2%	3.7%	3.5%	
REDDITUX	TRPHARM	Biosimilar (Turkey)	€ 4,185,986	€ 5,053,948	€ 5,152,347	○ € 4,797,427	Decline	-17%	-2%	7%	-7%		0.4%	0.4%	0.4%	0.4%	
Rituximab Biosimilars Total			€ 867,203,066	€ 821,142,533	€ 824,931,582	€ 837,759,060	Growth	6%	0%	-2%	2%		75.3%	70.8%	62.5%	69.2%	
MABTHERA	ROCHE	Reference Product	€ 270,031,169	€ 318,573,283	€ 465,059,783	€ 351,221,412	Decline	-15%	-31%	32%	-17%		23.4%	27.5%	35.2%	29.0%	
R-MAB	NATIVITA BELARUS	Non Reference Product (Belarus)	€ 718,725	€ 773,152	€ 2,021,771	€ 1,171,216	Decline	-7%	-62%	73%	-29%		0.1%	0.1%	0.2%	0.1%	
Generics Total			€ 13,847,576	€ 18,744,433	€ 28,530,986	€ 20,374,332		-26%	-34%	40%	-21%		1.2%	1.6%	2.2%	1.7%	
TOTAL			€ 1,151,800,536	€ 1,159,233,401	€ 1,320,544,122	€ 1,210,526,020	DEGROWING	-1%	-12%	9%	-4%		100.0%	100.0%	100.0%	100.0%	



- Market Share:

Rituximab biosimilars had a total market share of 62.5% in 2020, which increased to 70.8% in 2021, and further increased to 75.3% in 2022. This indicates that the market for Rituximab biosimilars is expanding, and they are gaining popularity among patients and healthcare providers.

RITUXIMAB

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
BLITZIMA	OKTAL PHARMA	Biosimilar (EMA)	€ 2,898,579	€ 3,897,593	€ 4,705,530	○ € 3,833,901	Decline	-26%	-17%	-21%	-15%		0.3%	0.3%	0.4%	0.3%
RITEMVIA	ASTRO-PHARMA GMBH	Biosimilar (EMA)	Discontinued (EMA Mrktng auth. ended in Aug '21)		€ 1,915,576	○ € 1,915,576	Withdrawn		-100%		-100%			0.0%	0.1%	0.2%
RIXATHON	NOVARTIS	Biosimilar (EMA)	€ 526,036,731	€ 401,576,986	€ 333,910,074	● € 420,507,930	Growth	31%	20%	26%	16%		45.7%	34.6%	25.3%	34.7%
RUXIENCE	PFIZER	Biosimilar (EMA)	€ 72,006,045	€ 31,223,652	€ 395,322	○ € 34,541,673	Growth	131%	7798%		467%		6.3%	2.7%	0.0%	2.9%
TRUXIMA	CELLTRION	Biosimilar (EMA)	€ 221,402,056	€ 342,586,432	€ 429,854,148	● € 331,280,879	Decline	-35%	-20%	-28%	-20%		19.2%	29.6%	32.6%	27.4%
ACELLBIA	BIOCAD	Biosimilar (Russia)	€ 40,673,669	€ 36,803,922	€ 48,998,585	○ € 42,158,725	Recovery	11%	-25%	16%	-6%		3.5%	3.2%	3.7%	3.5%
REDDITUX	TRPHARM	Biosimilar (Turkey)	€ 4,185,986	€ 5,053,948	€ 5,152,347	○ € 4,797,427	Decline	-17%	-2%	7%	-7%		0.4%	0.4%	0.4%	0.4%
Rituximab Biosimilars Total			€ 867,203,066	€ 821,142,533	€ 824,931,582	€ 837,759,060	Growth	6%	0%	-2%	2%		75.3%	70.8%	62.5%	69.2%
MABTHERA	ROCHE	Reference Product	€ 270,031,169	€ 318,573,283	€ 465,059,783	€ 351,221,412	Decline	-15%	-31%	32%	-17%		23.4%	27.5%	35.2%	29.0%
R-MAB	NATIVITA BELARUS	Non Reference Product (Belarus)	€ 718,725	€ 773,152	€ 2,021,771	€ 1,171,216	Decline	-7%	-62%	73%	-29%		0.1%	0.1%	0.2%	0.1%
Generics Total			€ 13,847,576	€ 18,744,433	€ 28,530,986	€ 20,374,332	Decline	-26%	-34%	40%	-21%		1.2%	1.6%	2.2%	1.7%
TOTAL			€ 1,151,800,536	€ 1,159,233,401	€ 1,320,544,122	€ 1,210,526,020	DEGROWING	-1%	-12%	9%	-4%		100.0%	100.0%	100.0%	100.0%



- Revenue:

The revenue generated by Rituximab biosimilars in 2022 was € 0.86 bn. which represents a growth of 6% compared to 2021. The average revenue for the past three years was € 0.83 bn., which is slightly lower than the revenue generated in 2022. However, the revenue trend for Rituximab biosimilars has been mixed over the past three years, with a decline in 2020, followed by a slight increase in 2021 and a further increase in 2022.

RITUXIMAB

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
BLITZIMA	OKTAL PHARMA	Biosimilar (EMA)	€ 2,898,579	€ 3,897,593	€ 4,705,530	○ € 3,833,901	Decline	-26%	-17%	-21%	-15%		0.3%	0.3%	0.4%	0.3%
RITEMVIA	ASTRO-PHARMA GMBH	Biosimilar (EMA)	Discontinued (EMA Mrktng auth. ended in Aug '21)		€ 1,915,576	○ € 1,915,576	Withdrawn		-100%		-100%			0.0%	0.1%	0.2%
RIXATHON	NOVARTIS	Biosimilar (EMA)	€ 526,036,731	€ 401,576,986	€ 333,910,074	● € 420,507,930	Growth	31%	20%	26%	16%		45.7%	34.6%	25.3%	34.7%
RUXIENCE	PFIZER	Biosimilar (EMA)	€ 72,006,045	€ 31,223,652	€ 395,322	○ € 34,541,673	Growth	131%	7798%		467%		6.3%	2.7%	0.0%	2.9%
TRUXIMA	CELLTRION	Biosimilar (EMA)	€ 221,402,056	€ 342,586,432	€ 429,854,148	● € 331,280,879	Decline	-35%	-20%	-28%	-20%		19.2%	29.6%	32.6%	27.4%
ACELLBIA	BIOCAD	Biosimilar (Russia)	€ 40,673,669	€ 36,803,922	€ 48,998,585	○ € 42,158,725	Recovery	11%	-25%	16%	-6%		3.5%	3.2%	3.7%	3.5%
REDDITUX	TRPHARM	Biosimilar (Turkey)	€ 4,185,986	€ 5,053,948	€ 5,152,347	○ € 4,797,427	Decline	-17%	-2%	7%	-7%		0.4%	0.4%	0.4%	0.4%
Rituximab Biosimilars Total			€ 867,203,066	€ 821,142,533	€ 824,931,582	€ 837,759,060	Growth	6%	0%	-2%	2%		75.3%	70.8%	62.5%	69.2%
MABTHERA	ROCHE	Reference Product	€ 270,031,169	€ 318,573,283	€ 465,059,783	€ 351,221,412	Decline	-15%	-31%	32%	-17%		23.4%	27.5%	35.2%	29.0%
R-MAB	NATIVITA BELARUS	Non Reference Product (Belarus)	€ 718,725	€ 773,152	€ 2,021,771	€ 1,171,216	Decline	-7%	-62%	73%	-29%		0.1%	0.1%	0.2%	0.1%
Generics Total			€ 13,847,576	€ 18,744,433	€ 28,530,986	€ 20,374,332	Decline	-26%	-34%	40%	-21%		1.2%	1.6%	2.2%	1.7%
TOTAL			€ 1,151,800,536	€ 1,159,233,401	€ 1,320,544,122	€ 1,210,526,020	DEGROWING	-1%	-12%	9%	-4%		100.0%	100.0%	100.0%	100.0%



- **Brand Performance:**

Among the various brands of Rituximab biosimilars, RIXATHON by Novartis has the highest market share of 45.7% in 2022, followed by TRUXIMA by Celltrion with a market share of 19.2%. However, RUXIENCE by Pfizer has shown the highest growth rate, with a YoY GR of 131% in 2022, although its market share is still relatively low at 2.9%.

RITUXIMAB

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
BLITZIMA	OKTAL PHARMA	Biosimilar (EMA)	€ 2,898,579	€ 3,897,593	€ 4,705,530	○ € 3,833,901	Decline	-26%	-17%	-21%	-15%		0.3%	0.3%	0.4%	0.3%
RITEMVIA	ASTRO-PHARMA GMBH	Biosimilar (EMA)	Discontinued (EMA Mrktng auth. ended in Aug '21)		€ 1,915,576	○ € 1,915,576	Withdrawn		-100%		-100%			0.0%	0.1%	0.2%
RIXATHON	NOVARTIS	Biosimilar (EMA)	€ 526,036,731	€ 401,576,986	€ 333,910,074	● € 420,507,930	Growth	31%	20%	26%	16%		45.7%	34.6%	25.3%	34.7%
RUXIENCE	PFIZER	Biosimilar (EMA)	€ 72,006,045	€ 31,223,652	€ 395,322	○ € 34,541,673	Growth	131%	7798%		467%		6.3%	2.7%	0.0%	2.9%
TRUXIMA	CELLTRION	Biosimilar (EMA)	€ 221,402,056	€ 342,586,432	€ 429,854,148	● € 331,280,879	Decline	-35%	-20%	-28%	-20%		19.2%	29.6%	32.6%	27.4%
ACELBIA	BIOCAD	Biosimilar (Russia)	€ 40,673,669	€ 36,803,922	€ 48,998,585	○ € 42,158,725	Recovery	11%	-25%	16%	-6%		3.5%	3.2%	3.7%	3.5%
REDDITUX	TRPHARM	Biosimilar (Turkey)	€ 4,185,986	€ 5,053,948	€ 5,152,347	○ € 4,797,427	Decline	-17%	-2%	7%	-7%		0.4%	0.4%	0.4%	0.4%
Rituximab Biosimilars Total			€ 867,203,066	€ 821,142,533	€ 824,931,582	€ 837,759,060	Growth	6%	0%	-2%	2%		75.3%	70.8%	62.5%	69.2%
MABTHERA	ROCHE	Reference Product	€ 270,031,169	€ 318,573,283	€ 465,059,783	€ 351,221,412	Decline	-15%	-31%	32%	-17%		23.4%	27.5%	35.2%	29.0%
R-MAB	NATIVITA BELARUS	Non Reference Product (Belarus)	€ 718,725	€ 773,152	€ 2,021,771	€ 1,171,216	Decline	-7%	-62%	73%	-29%		0.1%	0.1%	0.2%	0.1%
Generics Total			€ 13,847,576	€ 18,744,433	€ 28,530,986	€ 20,374,332	Decline	-26%	-34%	40%	-21%		1.2%	1.6%	2.2%	1.7%
TOTAL			€ 1,151,800,536	€ 1,159,233,401	€ 1,320,544,122	€ 1,210,526,020	DEGROWING	-1%	-12%	9%	-4%		100.0%	100.0%	100.0%	100.0%



- Discontinued Product:

RITEMVIA by Astro-Pharma GmbH was discontinued in August 2021, and its marketing authorization ended in the EMA market. This has resulted in a decline in its market share to 0.0% in 2022.

RITUXIMAB

Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS	
BLITZIMA	OKTAL PHARMA	Biosimilar (EMA)	€ 2,898,579	€ 3,897,593	€ 4,705,530	○ € 3,833,901	Decline	-26%	-17%	-21%	-15%		0.3%	0.3%	0.4%	0.3%	
RITEMVIA	ASTRO-PHARMA GMBH	Biosimilar (EMA)	Discontinued (EMA Mrktng auth. ended in Aug '21)			€ 1,915,576	○ € 1,915,576	Withdrawn		-100%		-100%			0.0%	0.1%	0.2%
RIXATHON	NOVARTIS	Biosimilar (EMA)	€ 526,036,731	€ 401,576,986	€ 333,910,074	● € 420,507,930	Growth	31%	20%	26%	16%		45.7%	34.6%	25.3%	34.7%	
RUXIENCE	PFIZER	Biosimilar (EMA)	€ 72,006,045	€ 31,223,652	€ 395,322	○ € 34,541,673	Growth	131%	7798%		467%		6.3%	2.7%	0.0%	2.9%	
TRUXIMA	CELLTRION	Biosimilar (EMA)	€ 221,402,056	€ 342,586,432	€ 429,854,148	● € 331,280,879	Decline	-35%	-20%	-28%	-20%		19.2%	29.6%	32.6%	27.4%	
ACELLBIA	BIOCAD	Biosimilar (Russia)	€ 40,673,669	€ 36,803,922	€ 48,998,585	○ € 42,158,725	Recovery	11%	-25%	16%	-6%		3.5%	3.2%	3.7%	3.5%	
REDDITUX	TRPHARM	Biosimilar (Turkey)	€ 4,185,986	€ 5,053,948	€ 5,152,347	○ € 4,797,427	Decline	-17%	-2%	7%	-7%		0.4%	0.4%	0.4%	0.4%	
Rituximab Biosimilars Total			€ 867,203,066	€ 821,142,533	€ 824,931,582	€ 837,759,060	Growth	6%	0%	-2%	2%		75.3%	70.8%	62.5%	69.2%	
MABTHERA	ROCHE	Reference Product	€ 270,031,169	€ 318,573,283	€ 465,059,783	€ 351,221,412	Decline	-15%	-31%	32%	-17%		23.4%	27.5%	35.2%	29.0%	
R-MAB	NATIVITA BELARUS	Non Reference Product (Belarus)	€ 718,725	€ 773,152	€ 2,021,771	€ 1,171,216	Decline	-7%	-62%	73%	-29%		0.1%	0.1%	0.2%	0.1%	
Generics Total			€ 13,847,576	€ 18,744,433	€ 28,530,986	€ 20,374,332		-26%	-34%	40%	-21%		1.2%	1.6%	2.2%	1.7%	
TOTAL			€ 1,151,800,536	€ 1,159,233,401	€ 1,320,544,122	€ 1,210,526,020	DEGROWING	-1%	-12%	9%	-4%		100.0%	100.0%	100.0%	100.0%	



TRASTUZUMAB

Market Overview:

Trastuzumab is a widely used drug in the treatment of HER2 positive breast cancer. In Europe, the trastuzumab market is dominated by biosimilars, with the reference product Herceptin from Roche experiencing a decline in sales. In terms of biosimilars, ONTRUZANT from Organon is the market leader in terms of revenue and market share in 2022 Q3. However, ELEFTHA from INTAS has shown the highest growth rate in revenue and market share from 2021 to 2022.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
(9) TRASTUZUMAB	ELEFTHA	INTAS	Biosimilar (EMA)	€ 16,015,822	€ 5,921,397		€ 10,968,610	Growth	170%					1.3%	0.4%	0.0%	0.8%
	HERTRAZ	VIATRIS	Biosimilar (EMA)	€ 63,132,471	€ 43,999,248	€ 29,454,026	€ 45,528,582	Growth	43%	49%	46%	29%		5.2%	3.3%	2.0%	3.4%
	HERZUMA	CELLTRION	Biosimilar (EMA)	€ 126,355,454	€ 166,158,203	€ 197,146,932	€ 163,220,196	Decline	-24%	-16%	-20%	-14%		10.5%	12.4%	13.1%	12.1%
	KANJINTI	AMGEN	Biosimilar (EMA)	€ 41,300,365	€ 66,854,593	€ 79,386,674	€ 62,513,877	Decline	-38%	-16%	-27%	-20%		3.4%	5.0%	5.3%	4.6%
	ONTRUZANT	ORGANON	Biosimilar (EMA)	€ 143,400,154	€ 169,269,122	€ 183,761,975	€ 165,477,084	Decline	-15%	-8%	-12%	-8%		11.9%	12.7%	12.2%	12.3%
	TRAZIMERA	PFIZER	Biosimilar (EMA)	€ 122,209,379	€ 104,924,278	€ 61,309,189	€ 96,147,615	Growth	16%	71%	44%	26%		10.1%	7.9%	4.1%	7.1%
	ZERCEPAC	PHARMAS	Biosimilar (EMA)	€ 727,181	€ 145,864		€ 436,523	Growth	399%					0.1%	0.0%	0.0%	0.0%
	HERTICAD	BIOCAD	Biosimilar (Russia)	€ 44,915,044	€ 39,045,274	€ 63,819,431	€ 49,259,916	Recovering	15%	-39%	-12%	26%		3.7%	2.9%	4.3%	3.7%
	CANHERA	ABDI IBRAHIM	Biosimilar (Turkey)	€ 1,779,257	€ 9,067,175	€ 5,560,917	€ 5,469,116	Decline	-80%	63%	-9%	26%		0.1%	0.7%	0.4%	0.4%
	Trastuzumab Biosimilars Total			€ 559,835,127	€ 605,385,154	€ 620,439,144	€ 595,219,808	Decline	-8%	-2%	-5%	26%		46.4%	45.3%	41.3%	44.2%
	HERCEPTIN	ROCHE	Reference Product	€ 640,605,679	€ 726,126,046	€ 873,358,307	€ 746,696,677	Decline	-12%	-17%	-14%	-10%		53.1%	54.3%	58.2%	55.4%
	All other non reference products T-MAB, CANMAB			€ 1,256,130	€ 1,021,787	€ 3,569,408	€ 1,949,108	Decline	23%	-71%	-24%	-29%		0.1%	0.1%	0.2%	0.1%
	Generics Total			€ 3,923,556	€ 3,820,845	€ 3,834,635	€ 3,859,679	Growth	3%	0%	1%	1%		0.3%	0.3%	0.3%	0.3%
	TOTAL			€ 1,205,620,492	€ 1,336,353,832	€ 1,501,201,494	€ 1,347,725,273	DEGWING	-10%	-11%	-10%	-7%		100.0%	100.0%	100.0%	100.0%



TRASTUZUMAB

Market Share:

In 2022 Q3, the biosimilar market for trastuzumab in Europe had a total revenue of €559.8 million. This represents a decline of 8% from the previous year. The biosimilar market had a market share of 46.4% in 2022 Q3, which is slightly lower than the market share of reference products and other non-reference products combined. Among the biosimilars, ONTRUZANT from Organon had the highest market share of 11.9% in 2022 Q3, followed by HERZUMA from Celltrion at 10.5%.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
(9) TRASTUZUMAB	ELEFTHA	INTAS	Biosimilar (EMA)	€ 16,015,822	€ 5,921,397		€ 10,968,610	Growth	170%					1.3%	0.4%	0.0%	0.8%
	HERTRAZ	VIATRIS	Biosimilar (EMA)	€ 63,132,471	€ 43,999,248	€ 29,454,026	€ 45,528,582	Growth	43%	49%	46%	29%		5.2%	3.3%	2.0%	3.4%
	HERZUMA	CELLTRION	Biosimilar (EMA)	€ 126,355,454	€ 166,158,203	€ 197,146,932	€ 163,220,196	Decline	-24%	-16%	-20%	-14%		10.5%	12.4%	13.1%	12.1%
	KANJINTI	AMGEN	Biosimilar (EMA)	€ 41,300,365	€ 66,854,593	€ 79,386,674	€ 62,513,877	Decline	-38%	-16%	-27%	-20%		3.4%	5.0%	5.3%	4.6%
	ONTRUZANT	ORGANON	Biosimilar (EMA)	€ 143,400,154	€ 169,269,122	€ 183,761,975	€ 165,477,084	Decline	-15%	-8%	-12%	-8%		11.9%	12.7%	12.2%	12.3%
	TRAZIMERA	PFIZER	Biosimilar (EMA)	€ 122,209,379	€ 104,924,278	€ 61,309,189	€ 96,147,615	Growth	16%	71%	44%	26%		10.1%	7.9%	4.1%	7.1%
	ZERCEPAC	PHARMAS	Biosimilar (EMA)	€ 727,181	€ 145,864		€ 436,523	Growth	399%					0.1%	0.0%	0.0%	0.0%
	HERTICAD	BIOCAD	Biosimilar (Russia)	€ 44,915,044	€ 39,045,274	€ 63,819,431	€ 49,259,916	Recovering	15%	-39%	-12%	26%		3.7%	2.9%	4.3%	3.7%
	CANHERA	ABDI IBRAHIM	Biosimilar (Turkey)	€ 1,779,257	€ 9,067,175	€ 5,560,917	€ 5,469,116	Decline	-80%	63%	-9%	26%		0.1%	0.7%	0.4%	0.4%
	Trastuzumab Biosimilars Total			€ 559,835,127	€ 605,385,154	€ 620,439,144	€ 595,219,808	Decline	-8%	-2%	-5%	26%		46.4%	45.3%	41.3%	44.2%
	HERCEPTIN	ROCHE	Reference Product	€ 640,605,679	€ 726,126,046	€ 873,358,307	€ 746,696,677	Decline	-12%	-17%	-14%	-10%		53.1%	54.3%	58.2%	55.4%
	All other non reference products T-MAB, CANMAB			€ 1,256,130	€ 1,021,787	€ 3,569,408	€ 1,949,108	Decline	23%	-71%	-24%	-29%		0.1%	0.1%	0.2%	0.1%
	Generics Total			€ 3,923,556	€ 3,820,845	€ 3,834,635	€ 3,859,679	Growth	3%	0%	1%	1%		0.3%	0.3%	0.3%	0.3%
	TOTAL			€ 1,205,620,492	€ 1,336,353,832	€ 1,501,201,494	€ 1,347,725,273	DEGWING	-10%	-11%	-10%	-7%		100.0%	100.0%	100.0%	100.0%



TRASTUZUMAB

• Revenue:

In terms of revenue, the biosimilar market for trastuzumab in Europe was led by Ontruzant from Organon, which generated €143.4 million in 2022 Q3. This was followed by HERZUMA from CELLTRION and TRAZIMERA from Pfizer, which generated €126.4 million and €122.2 million respectively. The biosimilar market saw a decline of 8% in revenue from the previous year. However, ZERCEPAC from PHARMAS showed the highest growth rate in revenue from 2021 to 2022, with an increase of 399%.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS	
(9) TRASTUZUMAB	ELEFTHA	INTAS	Biosimilar (EMA)	€ 16,015,822	€ 5,921,397		○ € 10,968,610	Growth	170%					1.3%	0.4%	0.0%	0.8%	
	HERTRAZ	VIATRIS	Biosimilar (EMA)	€ 63,132,471	€ 43,999,248	€ 29,454,026	🕒 € 45,528,582	Growth	43%	49%	46%	29%		5.2%	3.3%	2.0%	3.4%	
	HERZUMA	CELLTRION	Biosimilar (EMA)	€ 126,355,454	€ 166,158,203	€ 197,146,932	🕒 € 163,220,196	Decline	-24%	-16%	-20%	-14%		10.5%	12.4%	13.1%	12.1%	
	KANJINTI	AMGEN	Biosimilar (EMA)	€ 41,300,365	€ 66,854,593	€ 79,386,674	🕒 € 62,513,877	Decline	-38%	-16%	-27%	-20%		3.4%	5.0%	5.3%	4.6%	
	ONTRUZANT	ORGANON	Biosimilar (EMA)	€ 143,400,154	€ 169,269,122	€ 183,761,975	🕒 € 165,477,084	Decline	-15%	-8%	-12%	-8%		11.9%	12.7%	12.2%	12.3%	
	TRAZIMERA	PFIZER	Biosimilar (EMA)	€ 122,209,379	€ 104,924,278	€ 61,309,189	🕒 € 96,147,615	Growth	16%	71%	44%	26%		10.1%	7.9%	4.1%	7.1%	
	ZERCEPAC	PHARMAS	Biosimilar (EMA)	€ 727,181	€ 145,864		○ € 436,523	Growth	399%					0.1%	0.0%	0.0%	0.0%	
	HERTICAD	BIOCAD	Biosimilar (Russia)	€ 44,915,044	€ 39,045,274	€ 63,819,431	🕒 € 49,259,916	Recovering	15%	-39%	-12%	26%		3.7%	2.9%	4.3%	3.7%	
	CANHERA	ABDI IBRAHIM	Biosimilar (Turkey)	€ 1,779,257	€ 9,067,175	€ 5,560,917	○ € 5,469,116	Decline	-80%	63%	-9%	26%		0.1%	0.7%	0.4%	0.4%	
	Trastuzumab Biosimilars Total				€ 559,835,127	€ 605,385,154	€ 620,439,144	€ 595,219,808	Decline	-8%	-2%	-5%	26%		46.4%	45.3%	41.3%	44.2%
	HERCEPTIN	ROCHE	Reference Product	€ 640,605,679	€ 726,126,046	€ 873,358,307	€ 746,696,677	Decline	-12%	-17%	-14%	-10%		53.1%	54.3%	58.2%	55.4%	
	All other non reference products T-MAB, CANMAB				€ 1,256,130	€ 1,021,787	€ 3,569,408	€ 1,949,108	Decline	23%	-71%	-24%	-29%		0.1%	0.1%	0.2%	0.1%
	Generics Total				€ 3,923,556	€ 3,820,845	€ 3,834,635	€ 3,859,679	Growth	3%	0%	1%	1%		0.3%	0.3%	0.3%	0.3%
TOTAL				€ 1,205,620,492	€ 1,336,353,832	€ 1,501,201,494	€ 1,347,725,273	DEGROWING	-10%	-11%	-10%	-7%		100.0%	100.0%	100.0%	100.0%	



TRASTUZUMAB

• Growth Rate:

The YoY growth rate for the biosimilar market in 2021-22 was -8%, which was lower than the previous year. Among the biosimilars, ELEFTHA from INTAS showed the highest YoY growth rate of 170%. On the other hand, KANJINTI from AMGEN had the lowest YoY growth rate of -38%.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
(9) TRASTUZUMAB	ELEFTHA	INTAS	Biosimilar (EMA)	€ 16,015,822	€ 5,921,397		€ 10,968,610	Growth	170%					1.3%	0.4%	0.0%	0.8%
	HERTRAZ	VIATRIS	Biosimilar (EMA)	€ 63,132,471	€ 43,999,248	€ 29,454,026	€ 45,528,582	Growth	43%	49%	46%	29%		5.2%	3.3%	2.0%	3.4%
	HERZUMA	CELLTRION	Biosimilar (EMA)	€ 126,355,454	€ 166,158,203	€ 197,146,932	€ 163,220,196	Decline	-24%	-16%	-20%	-14%		10.5%	12.4%	13.1%	12.1%
	KANJINTI	AMGEN	Biosimilar (EMA)	€ 41,300,365	€ 66,854,593	€ 79,386,674	€ 62,513,877	Decline	-38%	-16%	-27%	-20%		3.4%	5.0%	5.3%	4.6%
	ONTRUZANT	ORGANON	Biosimilar (EMA)	€ 143,400,154	€ 169,269,122	€ 183,761,975	€ 165,477,084	Decline	-15%	-8%	-12%	-8%		11.9%	12.7%	12.2%	12.3%
	TRAZIMERA	PFIZER	Biosimilar (EMA)	€ 122,209,379	€ 104,924,278	€ 61,309,189	€ 96,147,615	Growth	16%	71%	44%	26%		10.1%	7.9%	4.1%	7.1%
	ZERCEPAC	PHARMAS	Biosimilar (EMA)	€ 727,181	€ 145,864		€ 436,523	Growth	399%					0.1%	0.0%	0.0%	0.0%
	HERTICAD	BIOCAD	Biosimilar (Russia)	€ 44,915,044	€ 39,045,274	€ 63,819,431	€ 49,259,916	Recovering	15%	-39%	-12%	26%		3.7%	2.9%	4.3%	3.7%
	CANHERA	ABDI IBRAHIM	Biosimilar (Turkey)	€ 1,779,257	€ 9,067,175	€ 5,560,917	€ 5,469,116	Decline	-80%	63%	-9%	26%		0.1%	0.7%	0.4%	0.4%
	Trastuzumab Biosimilars Total			€ 559,835,127	€ 605,385,154	€ 620,439,144	€ 595,219,808	Decline	-8%	-2%	-5%	26%		46.4%	45.3%	41.3%	44.2%
	HERCEPTIN	ROCHE	Reference Product	€ 640,605,679	€ 726,126,046	€ 873,358,307	€ 746,696,677	Decline	-12%	-17%	-14%	-10%		53.1%	54.3%	58.2%	55.4%
	All other non reference products T-MAB, CANMAB			€ 1,256,130	€ 1,021,787	€ 3,569,408	€ 1,949,108	Decline	23%	-71%	-24%	-29%		0.1%	0.1%	0.2%	0.1%
	Generics Total			€ 3,923,556	€ 3,820,845	€ 3,834,635	€ 3,859,679	Growth	3%	0%	1%	1%		0.3%	0.3%	0.3%	0.3%
	TOTAL			€ 1,205,620,492	€ 1,336,353,832	€ 1,501,201,494	€ 1,347,725,273	DEGWING	-10%	-11%	-10%	-7%		100.0%	100.0%	100.0%	100.0%



TRASTUZUMAB


• Brand Performance:

HERTRAZ from Viatris was the best performing biosimilar in Europe in 2022 Q3 in terms of both revenue and market share. The brand generated €63.1 million in revenue and had a market share of 5.2%. ELEFTHA from INTAS showed the highest growth rate in revenue and market share from 2021 to 2022. Among the reference products, Herceptin from Roche experienced a decline in sales, generating €640.6 million in revenue in 2022 Q3.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS	
(9) TRASTUZUMAB	ELEFTHA	INTAS	Biosimilar (EMA)	€ 16,015,822	€ 5,921,397		○ € 10,968,610	Growth	170%					1.3%	0.4%	0.0%	0.8%	
	HERTRAZ	VIATRIS	Biosimilar (EMA)	€ 63,132,471	€ 43,999,248	€ 29,454,026	🕒 € 45,528,582	Growth	43%	49%	46%	29%		5.2%	3.3%	2.0%	3.4%	
	HERZUMA	CELLTRION	Biosimilar (EMA)	€ 126,355,454	€ 166,158,203	€ 197,146,932	🕒 € 163,220,196	Decline	-24%	-16%	-20%	-14%		10.5%	12.4%	13.1%	12.1%	
	KANJINTI	AMGEN	Biosimilar (EMA)	€ 41,300,365	€ 66,854,593	€ 79,386,674	🕒 € 62,513,877	Decline	-38%	-16%	-27%	-20%		3.4%	5.0%	5.3%	4.6%	
	ONTRUZANT	ORGANON	Biosimilar (EMA)	€ 143,400,154	€ 169,269,122	€ 183,761,975	🕒 € 165,477,084	Decline	-15%	-8%	-12%	-8%		11.9%	12.7%	12.2%	12.3%	
	TRAZIMERA	PFIZER	Biosimilar (EMA)	€ 122,209,379	€ 104,924,278	€ 61,309,189	🕒 € 96,147,615	Growth	16%	71%	44%	26%		10.1%	7.9%	4.1%	7.1%	
	ZERCEPAC	PHARMAS	Biosimilar (EMA)	€ 727,181	€ 145,864		○ € 436,523	Growth	399%					0.1%	0.0%	0.0%	0.0%	
	HERTICAD	BIOCAD	Biosimilar (Russia)	€ 44,915,044	€ 39,045,274	€ 63,819,431	🕒 € 49,259,916	Recovering	15%	-39%	-12%	26%		3.7%	2.9%	4.3%	3.7%	
	CANHERA	ABDI IBRAHIM	Biosimilar (Turkey)	€ 1,779,257	€ 9,067,175	€ 5,560,917	○ € 5,469,116	Decline	-80%	63%	-9%	26%		0.1%	0.7%	0.4%	0.4%	
	Trastuzumab Biosimilars Total				€ 559,835,127	€ 605,385,154	€ 620,439,144	€ 595,219,808	Decline	-8%	-2%	-5%	26%		46.4%	45.3%	41.3%	44.2%
	HERCEPTIN	ROCHE	Reference Product	€ 640,605,679	€ 726,126,046	€ 873,358,307	€ 746,696,677	Decline	-12%	-17%	-14%	-10%		53.1%	54.3%	58.2%	55.4%	
	All other non reference products T-MAB, CANMAB				€ 1,256,130	€ 1,021,787	€ 3,569,408	€ 1,949,108	Decline	23%	-71%	-24%	-29%		0.1%	0.1%	0.2%	0.1%
	Generics Total				€ 3,923,556	€ 3,820,845	€ 3,834,635	€ 3,859,679	Growth	3%	0%	1%	1%		0.3%	0.3%	0.3%	0.3%
TOTAL				€ 1,205,620,492	€ 1,336,353,832	€ 1,501,201,494	€ 1,347,725,273	DEGROWING	-10%	-11%	-10%	-7%		100.0%	100.0%	100.0%	100.0%	

TRASTUZUMAB: Brand Performance

Herceptin-Revenue Vs Total Revenue-Trastuzumab




Herceptin remains the dominant brand, but its revenue is declining

BRANDS

Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Trazimera, T-MAB, Canmab

Year	Herceptin	TAM	Market Share
2020	€ 873.36	€ 1,501.20	58%
2021	€ 727.58	€ 1,345.13	54%
2022	€ 640.61	€ 1,205.62	53%

TRASTUZUMAB




Trazimera is experiencing rapid growth:

Trazimera has seen a significant increase in revenue, with a YoY growth rate of 17% in 2022 compared to 2021, and a YoY growth rate of 71% in 2021 compared to 2020. This could be due to its lower cost compared to Herceptin and its increasing popularity among customers.

Year	Trazimera	TAM	YoY GR
2022	€ 122.67	€ 1,501.20	17%
2021	€ 104.99	€ 1,345.13	71%
2020	€ 61.31	€ 1,205.62	-



ADALIMUMAB





ADALIMUMAB

- Market Overview:

Adalimumab is a popular biologic drug used to treat inflammatory conditions like rheumatoid arthritis and Crohn's disease. The European market for Adalimumab is dominated by biosimilar versions of the drug, which are manufactured by various companies. The reference product, Humira, is also available but faces increasing competition from biosimilars.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ADALIMUMAB (8)	AMGEVITA	AMGEN	Biosimilar	€ 771,813,251	€ 661,583,874	€ 544,740,230	● € 659,379,118	Growth	17%	21%	19%	12%		19.7%	18.1%	15.3%	17.7%
	HUKYNDRA	STADA	Biosimilar	€ 391,037			○ € 391,037	New launch						0.0%	0%	0%	0%
	HULIO	VIATRIS	Biosimilar	€ 229,042,634	€ 187,007,333	€ 116,598,361	● € 177,549,443	Growth	22%	60%	41%	25%		5.8%	5%	3%	5%
	HYRIMOZ	NOVARTIS	Biosimilar	€ 629,907,235	€ 484,802,507	€ 284,767,488	● € 466,492,410	Growth	30%	70%	50%	30%		16.1%	13%	8%	13%
	IDACIO	FRESENIUS	Biosimilar	€ 208,016,216	€ 80,597,476	€ 14,831,261	○ € 101,148,318	Growth	158%	443%	301%	141%		5.3%	2%	0%	3%
	IMRALDI	BIOGEN	Biosimilar	€ 595,552,671	€ 551,822,052	€ 462,358,151	● € 536,577,625	Growth	8%	19%	14%	9%		15.2%	15%	13%	14%
	XILBRILADA	PFIZER	Biosimilar	€ 2,286,686	€ 50,248		○ € 1,168,467	Growth	4451%					0.1%	0%	0%	0%
	YUFLYMA	CELLTRION	Biosimilar	€ 19,814,265	€ 440,074		○ € 10,127,170	Growth	4402%					0.5%	0%	0%	0%
	Adalimumab Biosimilars Total			€ 2,456,823,995	€ 1,966,303,564	€ 1,423,295,491	€ 1,948,807,683	Growth	25%	38%	32%	20%		62.7%	54%	40%	52%
	HUMIRA	ABBVIE GMBH	Reference Product	€ 1,446,497,944	€ 1,685,098,649	€ 2,126,696,915	€ 1,752,764,503	Decline	-14%	-21%	-17%	-12%		37%	46%	60%	47%
All other non reference products DALIBRA, ADALIRA, ADALIMAB, CINNORA, EXEMPTIA				€ 13,972,655	€ 11,104,570	€ 15,285,991	€ 13,454,405	Recovering	26%	-27%	-1%	-3%		0.4%	0%	0%	0%
Generics Total				€ 1,441			€ 1,441							0.0%	0%	0%	0%
TOTAL				€ 3,917,296,035	€ 3,662,506,783	€ 3,565,278,397	€ 3,715,027,072	GROWING	7%	3%	5%	3%		100.0%	100%	100%	100%



ADALIMUMAB

- Market Share:

As of Q3 2022, the biosimilar versions of Adalimumab hold a 62.7% market share in Europe, while Humira holds a 37% market share. Within the biosimilar market, the top-performing brands are Amgevita, Hyrimoz, and Imraldi, which together hold 51% of the market share

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ADALIMUMAB (8)	AMGEVITA	AMGEN	Biosimilar	€ 771,813,251	€ 661,583,874	€ 544,740,230	● € 659,379,118	Growth	17%	21%	19%	12%		19.7%	18.1%	15.3%	17.7%
	HUKYNDRA	STADA	Biosimilar	€ 391,037			○ € 391,037	New launch						0.0%	0%	0%	0%
	HULIO	VIATRIS	Biosimilar	€ 229,042,634	€ 187,007,333	€ 116,598,361	● € 177,549,443	Growth	22%	60%	41%	25%		5.8%	5%	3%	5%
	HYRIMOZ	NOVARTIS	Biosimilar	€ 629,907,235	€ 484,802,507	€ 284,767,488	● € 466,492,410	Growth	30%	70%	50%	30%		16.1%	13%	8%	13%
	IDACIO	FRESENIUS	Biosimilar	€ 208,016,216	€ 80,597,476	€ 14,831,261	○ € 101,148,318	Growth	158%	443%	301%	141%		5.3%	2%	0%	3%
	IMRALDI	BIOGEN	Biosimilar	€ 595,552,671	€ 551,822,052	€ 462,358,151	● € 536,577,625	Growth	8%	19%	14%	9%		15.2%	15%	13%	14%
	XILBRILADA	PFIZER	Biosimilar	€ 2,286,686	€ 50,248		○ € 1,168,467	Growth	4451%					0.1%	0%	0%	0%
	YUFLYMA	CELLTRION	Biosimilar	€ 19,814,265	€ 440,074		○ € 10,127,170	Growth	4402%					0.5%	0%	0%	0%
	Adalimumab Biosimilars Total			€ 2,456,823,995	€ 1,966,303,564	€ 1,423,295,491	€ 1,948,807,683	Growth	25%	38%	32%	20%		62.7%	54%	40%	52%
	HUMIRA	ABBVIE GMBH	Reference Product	€ 1,446,497,944	€ 1,685,098,649	€ 2,126,696,915	€ 1,752,764,503	Decline	-14%	-21%	-17%	-12%		37%	46%	60%	47%
All other non reference products DALIBRA, ADALIRA, ADALIMAB, CINNORA, EXEMPTIA				€ 13,972,655	€ 11,104,570	€ 15,285,991	€ 13,454,405	Recovering	26%	-27%	-1%	-3%		0.4%	0%	0%	0%
Generics Total				€ 1,441			€ 1,441							0.0%	0%	0%	0%
TOTAL				€ 3,917,296,035	€ 3,662,506,783	€ 3,565,278,397	€ 3,715,027,072	GROWING	7%	3%	5%	3%		100.0%	100%	100%	100%



ADALIMUMAB

- Revenue:

In Q3 2022, the Adalimumab market in Europe generated a total revenue of €2.46 billion, with biosimilars accounting for €1.29 billion and Humira accounting for €1.4 billion. The top-performing biosimilar brands are Amgevita, Hyrimoz, and Imraldi, which generated an average revenue of €659 million, €466 million, and €537 million, respectively.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ADALIMUMAB (8)	AMGEVITA	AMGEN	Biosimilar	€ 771,813,251	€ 661,583,874	€ 544,740,230	● € 659,379,118	Growth	17%	21%	19%	12%		19.7%	18.1%	15.3%	17.7%
	HUKYNDRA	STADA	Biosimilar	€ 391,037			○ € 391,037	New launch						0.0%	0%	0%	0%
	HULIO	VIATRIS	Biosimilar	€ 229,042,634	€ 187,007,333	€ 116,598,361	● € 177,549,443	Growth	22%	60%	41%	25%		5.8%	5%	3%	5%
	HYRIMOZ	NOVARTIS	Biosimilar	€ 629,907,235	€ 484,802,507	€ 284,767,488	● € 466,492,410	Growth	30%	70%	50%	30%		16.1%	13%	8%	13%
	IDACIO	FRESENIUS	Biosimilar	€ 208,016,216	€ 80,597,476	€ 14,831,261	○ € 101,148,318	Growth	158%	443%	301%	141%		5.3%	2%	0%	3%
	IMRALDI	BIOGEN	Biosimilar	€ 595,552,671	€ 551,822,052	€ 462,358,151	● € 536,577,625	Growth	8%	19%	14%	9%		15.2%	15%	13%	14%
	XILBRILADA	PFIZER	Biosimilar	€ 2,286,686	€ 50,248		○ € 1,168,467	Growth	4451%					0.1%	0%	0%	0%
	YUFLYMA	CELLTRION	Biosimilar	€ 19,814,265	€ 440,074		○ € 10,127,170	Growth	4402%					0.5%	0%	0%	0%
	Adalimumab Biosimilars Total			€ 2,456,823,995	€ 1,966,303,564	€ 1,423,295,491	€ 1,948,807,683	Growth	25%	38%	32%	20%		62.7%	54%	40%	52%
	HUMIRA	ABBVIE GMBH	Reference Product	€ 1,446,497,944	€ 1,685,098,649	€ 2,126,696,915	€ 1,752,764,503	Decline	-14%	-21%	-17%	-12%		37%	46%	60%	47%
All other non reference products DALIBRA, ADALIRA, ADALIMAB, CINNORA, EXEMPTIA				€ 13,972,655	€ 11,104,570	€ 15,285,991	€ 13,454,405	Recovering	26%	-27%	-1%	-3%		0.4%	0%	0%	0%
Generics Total				€ 1,441			€ 1,441							0.0%	0%	0%	0%
TOTAL				€ 3,917,296,035	€ 3,662,506,783	€ 3,565,278,397	€ 3,715,027,072	GROWING	7%	3%	5%	3%		100.0%	100%	100%	100%



ADALIMUMAB

• Growth Rate:

The Adalimumab market in Europe has seen significant growth in recent years, with an average annual growth rate (AAGR) of **31.55%** from 2020-2022. The compound annual growth rate (CAGR) during this period was 24.67%. YoY growth rate from 2020-2021 was 38.15% and YoY growth rate from 2021-2022 was 24.95%.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ADALIMUMAB (8)	AMGEVITA	AMGEN	Biosimilar	€ 771,813,251	€ 661,583,874	€ 544,740,230	● € 659,379,118	Growth	17%	21%	19%	12%		19.7%	18.1%	15.3%	17.7%
	HUKYNDRA	STADA	Biosimilar	€ 391,037			○ € 391,037	New launch						0.0%	0%	0%	0%
	HULIO	VIATRIS	Biosimilar	€ 229,042,634	€ 187,007,333	€ 116,598,361	● € 177,549,443	Growth	22%	60%	41%	25%		5.8%	5%	3%	5%
	HYRIMOZ	NOVARTIS	Biosimilar	€ 629,907,235	€ 484,802,507	€ 284,767,488	● € 466,492,410	Growth	30%	70%	50%	30%		16.1%	13%	8%	13%
	IDACIO	FRESENIUS	Biosimilar	€ 208,016,216	€ 80,597,476	€ 14,831,261	○ € 101,148,318	Growth	158%	443%	301%	141%		5.3%	2%	0%	3%
	IMRALDI	BIOGEN	Biosimilar	€ 595,552,671	€ 551,822,052	€ 462,358,151	● € 536,577,625	Growth	8%	19%	14%	9%		15.2%	15%	13%	14%
	XILBRILADA	PFIZER	Biosimilar	€ 2,286,686	€ 50,248		○ € 1,168,467	Growth	4451%					0.1%	0%	0%	0%
	YUFLYMA	CELLTRION	Biosimilar	€ 19,814,265	€ 440,074		○ € 10,127,170	Growth	4402%					0.5%	0%	0%	0%
	Adalimumab Biosimilars Total			€ 2,456,823,995	€ 1,966,303,564	€ 1,423,295,491	€ 1,948,807,683	Growth	25%	38%	32%	20%		62.7%	54%	40%	52%
	HUMIRA	ABBVIE GMBH	Reference Product	€ 1,446,497,944	€ 1,685,098,649	€ 2,126,696,915	€ 1,752,764,503	Decline	-14%	-21%	-17%	-12%		37%	46%	60%	47%
All other non reference products DALIBRA, ADALIRA, ADALIMAB, CINNORA, EXEMPTIA				€ 13,972,655	€ 11,104,570	€ 15,285,991	€ 13,454,405	Recovering	26%	-27%	-1%	-3%		0.4%	0%	0%	0%
Generics Total				€ 1,441			€ 1,441							0.0%	0%	0%	0%
TOTAL				€ 3,917,296,035	€ 3,662,506,783	€ 3,565,278,397	€ 3,715,027,072	GROWING	7%	3%	5%	3%		100.0%	100%	100%	100%



ADALIMUMAB

- Brand Performance:

Among the biosimilar brands, Amgevita has been the top performer with a market share of 19.70% in Q3 2022 and an average YoY growth rate of 16.66%. Hyrimoz has the second-highest market share of 12.56% in Q3 2022 with an average YoY growth rate of 29.93%. Imraldi has a market share of 14.90% in Q3 2022 and an average YoY growth rate of 7.93%.

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
ADALIMUMAB (8)	AMGEVITA	AMGEN	Biosimilar	€ 771,813,251	€ 661,583,874	€ 544,740,230	● € 659,379,118	Growth	17%	21%	19%	12%		19.7%	18.1%	15.3%	17.7%
	HUKYNDRA	STADA	Biosimilar	€ 391,037			○ € 391,037	New launch						0.0%	0%	0%	0%
	HULIO	VIATRIS	Biosimilar	€ 229,042,634	€ 187,007,333	€ 116,598,361	● € 177,549,443	Growth	22%	60%	41%	25%		5.8%	5%	3%	5%
	HYRIMOZ	NOVARTIS	Biosimilar	€ 629,907,235	€ 484,802,507	€ 284,767,488	● € 466,492,410	Growth	30%	70%	50%	30%		16.1%	13%	8%	13%
	IDACIO	FRESENIUS	Biosimilar	€ 208,016,216	€ 80,597,476	€ 14,831,261	○ € 101,148,318	Growth	158%	443%	301%	141%		5.3%	2%	0%	3%
	IMRALDI	BIOGEN	Biosimilar	€ 595,552,671	€ 551,822,052	€ 462,358,151	● € 536,577,625	Growth	8%	19%	14%	9%		15.2%	15%	13%	14%
	XILBRILADA	PFIZER	Biosimilar	€ 2,286,686	€ 50,248		○ € 1,168,467	Growth	4451%					0.1%	0%	0%	0%
	YUFLYMA	CELLTRION	Biosimilar	€ 19,814,265	€ 440,074		○ € 10,127,170	Growth	4402%					0.5%	0%	0%	0%
	Adalimumab Biosimilars Total			€ 2,456,823,995	€ 1,966,303,564	€ 1,423,295,491	€ 1,948,807,683	Growth	25%	38%	32%	20%		62.7%	54%	40%	52%
	HUMIRA	ABBVIE GMBH	Reference Product	€ 1,446,497,944	€ 1,685,098,649	€ 2,126,696,915	€ 1,752,764,503	Decline	-14%	-21%	-17%	-12%		37%	46%	60%	47%
All other non reference products DALIBRA, ADALIRA, ADALIMAB, CINNORA, EXEMPTIA				€ 13,972,655	€ 11,104,570	€ 15,285,991	€ 13,454,405	Recovering	26%	-27%	-1%	-3%		0.4%	0%	0%	0%
Generics Total				€ 1,441			€ 1,441							0.0%	0%	0%	0%
TOTAL				€ 3,917,296,035	€ 3,662,506,783	€ 3,565,278,397	€ 3,715,027,072	GROWING	7%	3%	5%	3%		100.0%	100%	100%	100%



FILGRASTIM

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS	
(9) FILGRASTIM	ACCOFIL EBB>>	EBB MEDICAL AB	Biosimilar (EMA)	€ 26,321	€ 859		€ 13,590	Growth	2964%					0.0%	0.0%	0.0%	0.0%	
	FILGRASTIM NOVOT	NOVARTIS	Biosimilar (Germany)	€ 20,887,251	€ 22,707,364	€ 21,288,066	€ 21,627,560	Decline	-8%	7%		-1%		4.5%	4.9%	4.8%	4.7%	
	FILGRASTIM TEVA	TEVA	Biosimilar (Switzerland)	€ 4,212,919	€ 3,943,202	€ 3,836,372	€ 3,997,498	Growth	7%	3%	5%	-18%		0.9%	0.9%	0.9%	0.9%	
	GRASALVA	TEVA	Biosimilar (EMA)	€ 6,807,813	€ 10,329,788	€ 12,267,548	€ 9,801,716	Decline	-34%	-16%	-25%	-18%		1.5%	2.2%	2.7%	2.1%	
	GRASTOFIL	STADA	Biosimilar (EMA)		€ 33,652	€ 335,495	€ 184,574	Decline	-100%	-90%	-95%	-100%		0.0%	0.0%	0.1%	0.0%	
	NEUKINE	INTAS	Biosimilar (EMA)	€ 99,543,247	€ 74,401,904	€ 68,329,158	€ 80,758,103	Growth	34%	9%	21%	13%		21.3%	16.2%	15.3%	17.6%	
	NIVESTIM	PFIZER	Biosimilar (EMA)	€ 96,788,505	€ 99,122,305	€ 92,080,966	€ 95,997,259	Growth	-2%	8%	3%	2%		20.7%	21.5%	20.6%	20.9%	
	RATIOGRASTIM	TEVA	Biosimilar (EMA)	€ 6,592,531	€ 6,965,581	€ 7,166,524	€ 6,908,212	Decline	-5%	-3%	-4%	-3%		1.4%	1.5%	1.6%	1.5%	
	ZARZIO	NOVARTIS	Biosimilar (EMA)	€ 166,986,589	€ 176,660,843	€ 180,776,551	€ 174,807,994	Decline	-5%	-2%		-3%		35.7%	38.4%	40.4%	38.1%	
	Filgrastim Biosimilars Total				€ 401,845,176	€ 394,165,498	€ 386,080,680		Growth	2%	2%	2%	-18%		86.0%	85.6%	86.3%	0.0%
	GRANULOKINE	AMGEN	Reference Product	€ 3,841	€ 60,201	€ 67,690	€ 43,911	Decline	-94%	-11%	-52%	-62%		0.0%	0.0%	0.0%	0.0%	
	NEUPOGEN	AMGEN	Reference Product	€ 30,892,738	€ 39,655,490	€ 40,543,180	€ 37,030,469	Decline	-22%	-2%	-12%	-9%		6.6%	8.6%	9.1%	8.1%	
	All other non reference products FRAVEN, LEUCOSTIM, NEUPOMAX, GRANOGEN, LEUCOCIM, MYELASTRA, LEICITA, NEUTROMAX				€ 21,020,563	€ 14,966,169	€ 15,671,072	€ 17,219,268	Growth	40%	-4%	18%	10%		5%	3%	4%	4%
	Generics Total				€ 13,344,729	€ 11,619,078	€ 5,096,041	€ 10,019,949	Growth	15%	128%	71%	38%		3%	3%	1%	2%
	TOTAL				€ 467,107,047	€ 460,466,436	€ 447,458,663	€ 458,344,049	Growth	1%	3%	2%	0%		100.0%	100.0%	100.0%	100.0%



PEGFILGRASTIM

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
(8) PEGFILGRASTIM	CEGFILA	STADA	Biosimilar (EMA)	€ 5,705,416	€ 3,553,677	€ 141,572	€ 3,133,555	Growth	61%	2410%	1235%	243%		1.4%	0.8%	0.0%	0.8%
	FULPHILA	VIATRIS	Biosimilar (EMA)	€ 18,908,871	€ 12,138,375	€ 834,971	€ 10,627,406	Growth	56%	1354%		181%		4.5%	2.8%	0.2%	2.6%
	GRASUSTEK	JUTA PHARMA/Q-PHA.	Biosimilar (EMA)	€ 9,745,529	€ 8,090,755	€ 1,860,482	€ 6,565,589	Growth	20%	335%	178%	73%		2.3%	1.9%	0.5%	1.6%
	NEUPEG	INTAS	Biosimilar (EMA)	€ 108,331,447	€ 114,006,142	€ 90,987,884	€ 104,441,824	Recovering	-5%	25%	10%	3%		25.8%	26.6%	22.7%	25.1%
	NYVEPRIA	PFIZER	Biosimilar (EMA)	€ 10,093,519	€ 2,187,996		€ 6,140,758	Growth	361%					2.4%	0.5%	0.0%	1.5%
	PELGRAZ	PHARMAS	Biosimilar (EMA)	€ 807,699	€ 474,421	€ 212,385	€ 498,168	Growth	70%	123%	97%	56%		0.2%	0.1%	0.1%	0.1%
	PELMEG	MUNDIPHARMA INT	Biosimilar (EMA)	€ 55,899,400	€ 64,784,207	€ 55,436,178	€ 58,706,595	Decline	-14%	17%	2%	-1%		13.3%	15.1%	13.9%	14.1%
	ZIEXTENZO	NOVARTIS	Biosimilar (EMA)	€ 82,493,520	€ 53,134,772	€ 47,455,556	€ 61,027,949	Growth	55%	12%	34%	56%		19.6%	12.4%	11.9%	14.7%
	Pegfilgrastim Biosimilars Total			€ 291,985,401	€ 258,370,345	€ 196,929,028	€ 249,094,925	Growth	13%	31%	22%	56%		69.4%	60.3%	49.2%	59.8%
	NEULASTA	AMGEN	Reference Product	€ 126,872,202	€ 169,510,974	€ 203,211,250	€ 166,531,475	Decline	-25%	-17%	-21%	-15%		30.2%	39.6%	50.8%	40.0%
	All other non reference products NEULASTIM, PEGSTIM			€ 37,097	€ 66,192	€ 93,183	€ 65,491	Decline	-44%	-29%	-36%	-3%		0.01%	0.02%	0.02%	0.02%
	Generics Total			€ 1,634,979	€ 412,391		€ 1,023,685	Growth	296%			-3%		0.39%	0.10%	0.00%	0.25%
	TOTAL			€ 420,529,679	€ 428,359,902	€ 400,233,461	€ 416,374,347	Recovering	-2%	7%	3%	-3%		100.0%	100.0%	100.0%	100.0%



ETANERCEPT

Molecule	Brands	Corporation	Type	MAT 2022(Q3)	MAT 2021(Q3)	MAT 2020(Q3)	Average Revenue	Revenue Trend 2020 2021 2022	YoY GR (2021-22)	YoY GR (2020-21)	AAGR	CAGR	Market Share Trend 2020 2021 2022	MS 2022	MS 2021	MS 2020	Average MS
(4) ETANERCEPT	ALTEBREL	ARYOGEN	Biosimilar (Kazakhstan)	€ 819,393			○ € 819,393	New launch						0.1%	0.0%	0.0%	0.1%
	BENEPALI	BIOGEN	Biosimilar	€ 633,881,662	€ 646,461,737	€ 628,276,017	● € 636,206,472	Recovering	-2%	3%	0%	0%		43.5%	42.2%	39.2%	41.6%
	ERELZI	NOVARTIS	Biosimilar	€ 252,580,956	€ 196,377,153	€ 166,054,159	◐ € 205,004,089	Growing	29%	18%	23%	15%		17.3%	12.8%	10.4%	13.4%
	NEPEXTO	VIATRIS	Biosimilar	€ 13,556,452	€ 5,463,694	€ 97,515	○ € 6,372,554	Growing	148%	5503%	2826%	418%		0.9%	0.4%	0.0%	0.4%
	Etanercept Biosimilars Total			€ 900,838,463	€ 848,302,584	€ 794,427,691	€ 847,856,246	Growing	6%	7%	6%	4%		61.8%	55.3%	49.6%	55.4%
	ENBREL	PFIZER	Reference Product	€ 551,915,225	€ 684,531,768	€ 807,568,871	€ 681,338,621	Declining	-19%	-15%	-17%	-12%		37.9%	44.6%	50.4%	44.5%
	Generics Total			€ 4,628,093	€ 401,747	€ 454,361	€ 1,828,067	Growing	1052%	-12%	520%	117%		0.3%	0.0%	0.0%	0.1%
	TOTAL			€ 1,457,381,781	€ 1,533,236,099	€ 1,602,450,923	€ 1,531,022,934	Declining	-5%	-4%	-5%	-3%		100.0%	100.0%	100.0%	100.0%



Blue Berry Pharma Advisory



Thank You